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Abstract  
 
Nanomaterial use has increased as the properties of materials at the nanoscale differ substantially 
from bulk materials. However, there is still a lack of information concerning their impact on human 
health and environment.  
Part of this study investigated the hazard of copper oxide nanoparticles (CuO NPs), multi-wall carbon 
nanotubes, silicon dioxide, pigment Red 254 and cobalt coated tungsten carbide using an in vitro 
hepatocyte model (HepG2/C3A cell lines). Most of the work was then conducted on CuO NPs 
together with four Safer by Design modifications of the same NPs (either citrate, ascorbate, 
polyethylenimine (PEI) or polyvinylpyrrolidone coating) and on both copper amine and micronized 
copper formulations, investigating their potency as inhibitors of fungal growth and analysing the gene 
expression in vivo on inhalation and ingestion models (Wistar rats).  
Copper materials consistently exerted cytotoxicity to HepG2/C3A cells and induced cytokine 
production 24 hours post exposure. Micronized copper and ascorbate coated CuO were the most and 
the least toxic respectively.   
Copper amine was most effective at reducing the fungal growth of Coniophora puteana, Trametes 
versicolor and Gloeophyllum trabeum while ascorbate coating enhanced the antifungal effect of CuO 
NPs.  
In vivo, short-term inhalation studies (STIS) were performed with pristine, ascorbate and PEI 
coatings. All the materials upregulated tumour necrosis factor alpha (TNFα) in lung tissue; in the 
short-term oral study (STOS) with CuO NPs and micronized copper, only the latter downregulated 
chemokine C-X-C motif ligand 2 (CXCL2) in the liver and metallothionein 1A in the ileum. 
In conclusion, CuO NPs were relatively cytotoxic in vitro and induced pro-inflammatory responses 
both in vitro and in vivo. However, these NPs were ineffective as antifungal treatment while the 
ascorbate coating enhanced the antifungal effect together with a significant decrease of cytotoxicity 
in vitro. The other materials did not induce any significant cytotoxicity nor cytokine production in 
C3A cells. 
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"O frati," dissi, "che per cento milia 
perigli siete giunti a l'occidente, 
a questa tanto picciola vigilia 
 
d'i nostri sensi ch'è del rimanente 
non vogliate negar l'esperïenza, 
di retro al sol, del mondo sanza gente. 
 
Considerate la vostra semenza: 
fatti non foste a viver come bruti, 
ma per seguir virtute e canoscenza". 
 
 
                   Dante Alighieri (1265-1321) 
        La Divina Commedia 
Inferno: C. XXVI, vv. 112-120 
 
 
 
 
 
‘O brothers!’ I began, ‘who to the west 
through perils without number now have reach’d; 
to this the short remaining watch, that yet 
 
our senses have to wake,  
refuse not proof of the unpeopled world,  
following the track of Phoebus. 
 
Call to mind from whence ye sprang: 
ye were not form’d to live the life of brutes, 
but virtue to pursue and knowledge high’. 
                             
                            Dante Alighieri (1265-1321) 
               The Divine Comedy 
                                   The Harvard Classics.  1909–14. 
                                                 Inferno (Hell): C. XXVI, vv. 112-120 
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HEPATOCYTES AFTER 4-HOUR EXPOSURE IN THE PRESENCE AND ABSENCE OF FPG. DATA EXPRESSED AS 
AVERAGE % DNA IN TAIL +/- SEM (N=3). STAR INDICATES A P ≤ 0.001. ..... ERRORE. IL SEGNALIBRO NON È 
DEFINITO. 
FIGURE 2. 15. FPF-MODIFIED ALKALINE COMET ASSAY INTERFERENCE. PREVIOUS RESULTS OF DNA DAMAGE 
EXPRESSED AS DNA IN TAIL NORMALIZED BY POSITIVE CONTROL ON C3A HEPATOCYTES AFTER 4H 
EXPOSURE IN BOTH FPG POSITIVE (B) AND NEGATIVE (A) TREATMENTS. IN X-AXIS THE TWO SUB-LETHAL 
CONCENTRATION OF COPPER (1X AND 0.5X BMD20) AND THE INTERFERENCE REPRESENTING A CUO TOTAL 
CONCENTRATION OF 20.61 µG/ML IN THE LMPA ........................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 2. 16 ASSESSMENT OF CYTOTOXICITY OF THE PRISTINE CUO NPS AND THE FIVE MODIFIED CUO NPS 
ASSESSED BY ALAMAR BLUE ASSAY IN THE C3A HEPATOCYTE CELL LINE AT 24 HOURS.  EXPOSURE 
CONCENTRATION IS EXPRESSED IN µG/ML AND ANALYSIS IS CONDUCTED USING THE PROAST PACKAGE IN R 
SOFTWARE. THE DATA IS COMPILED FROM THREE SEPARATE EXPERIMENTS (N=3), AND EACH DATA POINT 
REPRESENTS THE MEAN OF THREE REPLICATES CONDUCTED ON THE SAME DAY. THE SEGMENTED LINES 
SHOW THE BMD20 ESTIMATED BY THE SOFTWARE AND AT THE BOTTOM END OF THE LEGEND THE UPPER AND 
LOWER BOUNDS OF THE CONFIDENCE INTERVAL. IN THE Y-AXIS, THE DATA ARE EXPRESSED AS 
FLUORESCENCE READING (RAW DATA) ACCORDING TO THE PROAST ANALYSIS WHILE THE X-AXIS 
EXPRESSES THE DOSE AS µG/ML OF CUO PRESENT IN THE DISPERSION. ......... ERRORE. IL SEGNALIBRO NON È 
DEFINITO. 
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FIGURE 2. 17 IL-8 PRODUCTION OF ASCORBATE MODIFIED CUO NPS (CUO_105) COMPARED TO THE PRISTINE 
CUO. Y-AXIS INDICATES THE OBSERVED CONCENTRATION EXPRESSED AS PICOGRAMS/ML (·1000) WHILE IN 
THE X-AXIS ARE INDICATED THE DIFFERENT SUBSTANCES ANALYSED. THE CONCENTRATIONS TESTED FOR 
EACH SUBSTANCE WERE CALCULATED AS THE TOTAL AMOUNT OF COPPER CONTAINED IN THE BMD20 OF 
CUO NPS AND WHILE SPECIFIED, HALF THIS CONCENTRATION (0.5X WAS USED). BARS INDICATE SD (N=3). 
BIO-PLEX MANAGER SOFTWARE 6.1. ......................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 2. 18 PRISTINE CUO, CUCO3, COPPER AMINE AND CUSO4 (ALAMAR BLUE ASSAY) IN THE C3A 
HEPATOCYTE CELL LINE AT 24 HOURS EXPRESSED IN µG/ML USING PROAST PACKAGE IN R SOFTWARE. THE 
DATA IS COMPILED FROM THREE SEPARATE EXPERIMENTS (N=3), AND EACH DATA POINT REPRESENTS THE 
MEAN OF THREE REPLICATES CONDUCTED ON THE SAME DAY. THE SEGMENTED LINES SHOW THE BMD20 
ESTIMATED BY THE SOFTWARE AND AT THE BOTTOM END OF THE LEGEND THE UPPER AND LOWER BOUNDS 
OF THE CONFIDENCE INTERVAL. IN THE Y-AXIS, THE DATA ARE EXPRESSED AS FLUORESCENCE READING 
(RAW DATA) ACCORDING TO THE PROAST ANALYSIS WHILE THE X-AXIS EXPRESSES THE DOSE AS µG/ML OF 
EQUIVALENT CU AMOUNT PRESENT IN THE DISPERSION. ............. ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 2. 19 IL-8 PRODUCTION ELICITED BY MICRONIZED COPPER AND COPPER AMINE COMPARED TO CUO NPS 
AND CUSO4 SALT. Y-AXIS INDICATES THE OBSERVED CONCENTRATION EXPRESSED AS PICOGRAMS/ML 
WHILE IN THE X-AXIS ARE INDICATED THE DIFFERENT SUBSTANCES ANALYSED. THE CONCENTRATIONS 
TESTED FOR EACH SUBSTANCE WERE CALCULATED AS THE TOTAL AMOUNT OF COPPER CONTAINED IN THE 
BMD20 OF CUO NPS AND WHILE SPECIFIED, HALF THIS CONCENTRATION (0.5). BARS INDICATE SD (N=3). 
BIO-PLEX MANAGER SOFTWARE V.6.1. ...................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
 
FIGURE 3. 1 TWO-LAYER MEA AGAR. 5ML OF COPPER-CONTAINING MEA AGAR WAS SPREAD ONTO A PRE-SETTLED 
LAYER OF SIMPLE MEA. ............................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 3. 2 AGAR DISPERSION. MEA CONTAINING A HOMOGENEOUS DISPERSION OF COPPER CONTENT. ..ERRORE. IL 
SEGNALIBRO NON È DEFINITO. 
FIGURE 3. 3 G. TRABEUM GROWING ON CUO NP LAYERED AGAR.  FUNGAL GROWTH AFTER ONE-WEEK 
INCUBATION; NO VISIBLE INHIBITION OF GROWTH WAS NOTICEABLE EVEN AT HIGH EXPOSURE 
CONCENTRATIONS....................................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 3. 4 C. PUTEANA GROWTH AFTER 1-WEEK INCUBATION AT 20ºC ON MALT EXTRACT AGAR SUPPLEMENTED 
(VIA DISPERSION) WITH DIFFERENT CONCENTRATIONS OF COPPER FROM EACH TREATMENT. THE Y-AXIS 
REPRESENTS THE DIAMETER OF EACH FUNGAL COLONY MEASURED IN CENTIMETRES, WITH 1 CM 
REPRESENTING THE SIZE OF THE ORIGINAL FUNGAL PLUG (RED LINE).  EACH BAR REPRESENTS THE MEAN 
DATA FROM TWO REPETITIONS (N=2), EACH CONDUCTED IN TRIPLICATE.  DATA WERE ANALYSED USING 
GRAPHPAD PRISM VERSION 6.0 AND ONE-WAY ANOVA (DUNNETT). ......... ERRORE. IL SEGNALIBRO NON È 
DEFINITO. 
FIGURE 3. 5 PICTURES OF C. PUTEANA CULTURED ON COPPER DISPERSED AGAR AFTER 7 DAYS OF GROWTH. ON 
THE LEFT (A, C, E, G) PICTURES TAKEN FROM ABOVE, WHILE ON THE RIGHT (B, D,  F, H) THE SAME CULTURE 
DISHES FROM UNDERNEATH SHOWING THE UNDERGOING PIGMENTATION PROCESS. ERRORE. IL SEGNALIBRO 
NON È DEFINITO. 
FIGURE 3. 6 C. PUTEANA AFTER 1-WEEK GROWTH IN MEA SUPPLEMENTED WITH 200ΜG OF COPPER FROM COPPER 
CARBONATE (A) AND ASCORBATE-COATED CUO NANOPARTICLES (B) DEMONSTRATING THE BEGINNING OF 
PRIMORDIUM GROWTH. ............................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 3. 7 T. VERSICOLOR GROWTH ON COPPER AGAR DISPERSION AFTER 1 WEEK. THE Y-AXIS REPRESENTS THE 
DIAMETER OF EACH FUNGAL COLONY MEASURED IN CENTIMETRES, WITH 1 CM REPRESENTING THE SIZE OF 
THE ORIGINAL FUNGAL PLUG (RED LINE).  EACH BAR REPRESENTS THE MEAN DATA FROM TWO REPETITIONS 
(N=2), EACH CONDUCTED IN TRIPLICATE.  DATA WERE ANALYSED USING GRAPHPAD PRISM VERSION 6.0 
AND ONE-WAY ANOVA (DUNNETT). ......................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 3. 8 PICTURES OF T. VERSICOLOR CULTURED ON COPPER DISPERSED AGAR. MEA SUPPLEMENTED WITH 
DIFFERENT CONCENTRATIONS OF COPPER FROM A PANEL OF DIFFERENT COPPER MATERIALS: CUO (A), CUO-
ASCORBATE (B), CUCO3 (C), CU-AMINE (D) AND CUSO4 (E). ... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 3. 9 G. TRABEUM GROWTH AFTER 1-WEEK INCUBATION AT 20ºC ON MEA SUPPLEMENTED WITH 
DIFFERENT CONCENTRATIONS OF COPPER CARBONATE (CUCO3), COPPER-AMINE, ASCORBATE-COATED 
COPPER OXIDE NM, PRISTINE COPPER OXIDE NM OR COPPER SULPHATE (CUSO4). THE Y-AXIS REPRESENTS 
THE DIAMETER OF EACH FUNGAL COLONY MEASURED IN CENTIMETRES, WITH 1 CM REPRESENTING THE SIZE 
OF THE ORIGINAL FUNGAL PLUG.  EACH BAR REPRESENTS THE MEAN DATA FROM TWO REPETITIONS, EACH 
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CONDUCTED IN TRIPLICATE (N=2).  DATA WERE ANALYSED USING GRAPHPAD PRISM VERSION 6.0 AND ONE-
WAY ANOVA (DUNNETT).......................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 3. 10 PICTURES OF G. TRABEUM ON MEA SUPPLEMENTED WITH DIFFERENT CONCENTRATIONS OF COPPER 
FROM A PANEL OF DIFFERENT COPPER MATERIALS: CUO AND CUO-ASCORBATE (A), CUSO4 (B), CUCO3 (C) 
AND CU-AMINE (D). ................................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 3. 11 COMPARISON OF BOTH LAYERED AND DISPERSED AGAR MODELS. THE POSSIBLE HYPOTHESIS OF 
FUNGAL GROWTH SHOWING WHY THE LAYERED AGAR REPRESENTING THE COATING MODEL (A) WAS NOT 
EFFECTIVE IF COMPARED TO THE DISPERSED ONE (B) REPRESENTING THE IMPREGNATION SYSTEM. THE RED 
DOTS REPRESENT THE NPS, WHILE THE PINK CIRCLE AND THE BLUE RAMIFICATIONS REPRESENT THE AGAR 
PLUG AND THE HYPHAE RESPECTIVELY. ...................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
 
FIGURE 4. 1 GENE EXPRESSION OF RAT LUNG TISSUE EXPOSED TO PRISTINE CUO NPS (DAY 6).  VALUES ARE 
EXPRESSED AS FOLD CHANGE COMPARED TO THE CONTROL  ± STANDARD DEVIATION.(N=3).  STATISTICAL 
ANALYSIS VIA ANOVA (DUNNETT) WAS PERFORMED, AND A CUTOFF LIMIT OF ±1.8 FOLD CHANGE WAS 
USED TO INDICATE PHYSIOLOGICAL SIGNIFICANCE. .................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 4. 2 GENE EXPRESSION OF RAT LIVER TISSUES AFTER INHALATION OF PRISTINE CUO NPS (DAY 6); MT1A 
RESULTS EXPRESSED AS FOLD CHANGE. ERROR BARS REPRESENT THE STANDARD DEVIATION (N=3). 
STATISTICAL ANALYSIS VIA ANOVA (DUNETT) WAS PERFORMED, AND A CUTOFF LIMIT OF ±1.8 FOLD 
CHANGE WAS USED TO INDICATE PHYSIOLOGICAL SIGNIFICANCE. ................ ERRORE. IL SEGNALIBRO NON È 
DEFINITO. 
FIGURE 4. 3GENE EXPRESSION OF RAT ILEUM TISSUES AFTER INHALATION OF PRISTINE CUO NPS (DAY 6); CD46 
RESULTS EXPRESSED AS FOLD CHANGE. ERROR BARS REPRESENT THE STANDARD DEVIATION (N=3). 
STATISTICAL ANALYSIS VIA ANOVA (DUNNETT) WAS PERFORMED, AND A CUTOFF LIMIT OF ±1.8 FOLD 
CHANGE WAS USED TO INDICATE PHYSIOLOGICAL SIGNIFICANCE. ................ ERRORE. IL SEGNALIBRO NON È 
DEFINITO. 
FIGURE 4. 4GENE EXPRESSION OF LUNG TISSUE TISSUES AFTER INHALATION OF MODIFIED CUO NPS (DAY 6) 
TREATED WITH MODIFIED PEI AND ASCORBATE CUO NMS. TNFΑ RESULTS ARE EXPRESSED AS LOG OF THE 
RELATIVE QUANTIFICATION (RQ) OR FOLD CHANGE INCREASE COMPARED TO THE CONTROL ± STANDARD 
DEVIATION (N=3).  STATISTICAL ANALYSIS WAS CONDUCTED USING ANOVA (DUNNETT). CUT OFF LIMIT 
±1.8-FOLD CHANGE USED TO INDICATE PHYSIOLOGICAL SIGNIFICANCE........ ERRORE. IL SEGNALIBRO NON È 
DEFINITO. 
FIGURE 4. 5 SUMMARY OF THE HISTOLOGY AND TOXICOKINETIC DATA OBTAINED AT RIVM. ...............ERRORE. IL 
SEGNALIBRO NON È DEFINITO. 
FIGURE 4. 6 SUMMARY OF THE CYTOKINE ANALYSIS PERFORMED AT HERIOT-WATT UNIVERSITY. ........ERRORE. IL 
SEGNALIBRO NON È DEFINITO. 
FIGURE 4. 7 SUMMARY OF THE EPIGENETICS AND MICROARRAY DATA OBTAINED BY KAROLINSKA INSTITUTET 
AND HEALTH CANADA. .............................................................. ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 4. 8 SUMMARY OF THE HISTOLOGY AND TOXICOKINETIC RESULTS FOR BOTH ASCORBATE AND PEI 
COATED CUO NPS OBTAINED AT RIVM. .................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 4. 9 SUMMARY OF THE CYTOKINE ANALYSIS PERFORMED AT HERIOT-WATT UNIVERSITY. .......ERRORE. IL 
SEGNALIBRO NON È DEFINITO. 
 
FIGURE 5. 1GENE EXPRESSION OF CXCL2 IN LIVER TISSUE FROM STOS (DAY 6) TREATED WITH CUO NPS AND 
CUCO3 NMS. VALUES ARE EXPRESSED AS LOG OF THE RELATIVE QUANTIFICATION (RQ) OR  FOLD CHANGE 
INCREASE OR DECREASE COMPARED TO THE CONTROL ± STANDARD DEVIATION (N=3).  STATISTICAL 
ANALYSIS WAS CONDUCTED USING ANOVA (DUNNETT). CUT OFF LIMIT ±1.8 FOLD CHANGE USED TO 
INDICATE PHYSIOLOGICAL SIGNIFICANCE. .................................. ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 5. 2 GENE EXPRESSION OF MT1A IN ILEUM TISSUE FROM STOS (DAY 6) TREATED WITH CUO NPS AND 
CUCO3 NMS. VALUES ARE EXPRESSED AS LOG OF THE RELATIVE QUANTIFICATION (RQ) OR  FOLD CHANGE 
INCREASE OR DECREASE COMPARED TO THE CONTROL ± STANDARD DEVIATION (N=3).  STATISTICAL 
ANALYSIS WAS CONDUCTED USING ANOVA (DUNNETT). CUT OFF LIMIT ±1.8 FOLD CHANGE USED TO 
INDICATE PHYSIOLOGICAL SIGNIFICANCE. .................................. ERRORE. IL SEGNALIBRO NON È DEFINITO. 
 
FIGURE 6. 1 CAR BUMPERS REALIZED WITH MWCNT IN LIGHTWEIGHT CONDUCTIVE PLASTIC. THE SAME 
PRODUCT HAS BEEN REALIZED WITH RED 254. PICTURE FROM DELIVERABLE D 1.3, AVAILABLE ONLINE AT 
WWW.SUN-FP7.EU. ...................................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
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FIGURE 6. 2 COMMERCIAL PANCAKE MIXTURE WITH HOMOGENEOUSLY DISPERSED NM-202. PICTURE FROM 
DELIVERABLE D 1.3, AVAILABLE ONLINE AT WWW.SUN-FP7.EU. ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 6. 3 PHOTOGRAPH OF FORMULATED PIGMENT IN PLASTIC PRESENTLY AVAILABLE AS GRANULATES AND 
PLATES. PICTURE FROM DELIVERABLE D 1.3, AVAILABLE ONLINE AT WWW.SUN-FP7.EU...............ERRORE. IL 
SEGNALIBRO NON È DEFINITO. 
FIGURE 6. 4 WCCO: DLS SIZE DISTRIBUTION MEASUREMENTS AT T0 AND T24 FOR CUO, WCCO AND SIO2, 
DISPERSED IN DMEM CULTURE MEDIUM SUPPLEMENTED WITH 10% FBS. PICTURE FROM DELIVERABLE D 
1.4, AVAILABLE ONLINE AT WWW.SUN-FP7.EU............................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 6. 5 SIO2 (NM 202) CHARACTERIZATION. BET ANALYSIS RESULTS ON THE TOP TABLE; TEM PRIMARY 
PARTICLE SIZE AND AGGREGATES FORMATION (A); XRD (B) AND DSL IN MILLI-Q WATER (C AND TABLE ON 
THE BOTTOM). PICTURES AND DATA FROM THE EUROPEAN COMMISSION'S JOINT RESEARCH CENTRE 
REPOSITORY (RASMUSSEN ET AL. 2013B)................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 6. 6 SIO2: DLS SIZE DISTRIBUTION MEASUREMENTS AT T0 AND T24 FOR CUO, WCCO AND SIO2, 
DISPERSED IN DMEM CULTURE MEDIUM SUPPLEMENTED WITH 10% FBS. DATA FROM DELIVERABLE D 1.4, 
AVAILABLE ONLINE AT WWW.SUN-FP7.EU. ................................. ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 6. 7 NC7000™ MULTIWALL CARBON NANOTUBES – SCALE: 100 NM – TEM. SOURCE: NANOCYL SAFETY DATA-
SHEET NC7000-V11. ................................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 6. 8 ORGANIC PIGMENT RED 254. TEM IMAGE OF THE NANO-FORM GRADE OF IRGAZIN PIGMENT (A 
GENERIC CHEMICAL FORMULA IS PRESENTED ON THE BOTTOM LEFT OF THE PICTURE) WHILE A SUMMARY OF 
THE CHARACTERIZATION DATA IS PRESENTED ON THE RIGHT SIDE. SOURCE:  HOFMANN ET AL., 2016.
 ................................................................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 6. 9 WCCO CYTOTOXICITY. ALAMAR BLUE ASSAY ON C3A HEPATOCYTE CELL LINE AT 24 HOURS 
EXPRESSED IN µG/ML USING PROAST PACKAGE (VERSION 38.9) VIA R SOFTWARE. THE DATA IS COMPILED 
FROM THREE SEPARATE EXPERIMENTS (N=3), AND EACH DATA POINT REPRESENTS THE VALUE OF EVERY 
SINGLE REPLICATE. THE SEGMENTED LINES SHOW THE BMD20 ESTIMATED BY THE SOFTWARE USING THE 
HILL MODEL AND AT THE BOTTOM END OF THE LEGEND THE UPPER AND LOWER BOUNDS OF THE CONFIDENCE 
INTERVAL. IN THE Y-AXIS, THE DATA ARE EXPRESSED AS FLUORESCENCE READING (RAW DATA) ACCORDING 
TO THE PROAST ANALYSIS WHILE THE X-AXIS EXPRESSES THE DOSE AS µG/ML OF EITHER WCCO OR COCL2 
PRESENT IN THE DISPERSION. ...................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 6. 10 SIO2 CYTOTOXICITY. ALAMAR BLUE ASSAY ON C3A HEPATOCYTE CELL LINE AT 24 HOURS 
EXPRESSED IN µG/ML USING PROAST PACKAGE (VERSION 38.9) VIA R SOFTWARE. THE DATA IS COMPILED 
FROM THREE SEPARATE EXPERIMENTS, AND EACH DATA POINT REPRESENTS THE VALUE OF EVERY SINGLE 
REPLICATE. THE BMD20 ESTIMATED BY THE SOFTWARE USING THE HILL MODEL AND AT THE BOTTOM END 
OF THE LEGEND THE UPPER AND LOWER BOUNDS OF THE CONFIDENCE INTERVAL. IN THE Y-AXIS, THE DATA 
ARE EXPRESSED AS FLUORESCENCE READING (RAW DATA) ACCORDING TO THE PROAST ANALYSIS WHILE 
THE X-AXIS EXPRESSES THE DOSE AS µG/ML OF NPS. .................. ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 6. 11 ORGANIC PIGMENT RED 254 CYTOTOXICITY. ALAMAR BLUE ASSAY ON C3A HEPATOCYTE CELL 
LINE AT 24 HOURS EXPRESSED IN µG/ML USING PROAST PACKAGE (VERSION 38.9) VIA R SOFTWARE. THE 
DATA IS COMPILED FROM THREE SEPARATE EXPERIMENTS (N=3), AND EACH DATA POINT REPRESENTS THE 
VALUE OF EVERY SINGLE REPLICATE. THE SEGMENTED LINES SHOW THE BMD20 ESTIMATED BY THE 
SOFTWARE USING THE HILL MODEL AND AT THE BOTTOM END OF THE LEGEND THE UPPER AND LOWER 
BOUNDS OF THE CONFIDENCE INTERVAL. IN THE Y-AXIS, THE DATA ARE EXPRESSED AS FLUORESCENCE 
READING (RAW DATA) ACCORDING TO THE PROAST ANALYSIS WHILE THE X-AXIS EXPRESSES THE DOSE AS 
µG/ML OF PIGMENT...................................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 6. 12 MWCNTS CYTOTOXICITY. ALAMAR BLUE ASSAY ON C3A HEPATOCYTE CELL LINE AT 24 HOURS 
EXPRESSED IN µG/ML USING PROAST PACKAGE (VERSION 38.9) VIA R SOFTWARE. THE DATA IS COMPILED 
FROM THREE SEPARATE EXPERIMENTS (N=3), AND EACH DATA POINT REPRESENTS THE VALUE OF EVERY 
SINGLE REPLICATE. THE SEGMENTED LINES SHOW THE BMD20 ESTIMATED BY THE SOFTWARE USING THE 
HILL MODEL AND AT THE BOTTOM END OF THE LEGEND THE UPPER AND LOWER BOUNDS OF THE CONFIDENCE 
INTERVAL. IN THE Y-AXIS, THE DATA ARE EXPRESSED AS FLUORESCENCE READING (RAW DATA) ACCORDING 
TO THE PROAST ANALYSIS WHILE THE X-AXIS EXPRESSES THE DOSE AS µG/ML OF MWCNTS. ...ERRORE. IL 
SEGNALIBRO NON È DEFINITO. 
FIGURE 6. 13 NPS INDUCED CYTOKINE PRODUCTION. IL-8 DETECTED IN C3A CELL LINE AFTER 24 HOURS 
EXPOSURE TO 0.5X AND 1X BMD20 VALUE OF WCCO, ORGANIC PIGMENT RED 254, SIO2 NPS AND COCL2 
SALT. ON THE Y-AXIS, THE CONCENTRATION OF IL-8 EXPRESSED AS PG/ML (X100). ERROR BAR: STANDARD 
DEVIATION (N=3). ...................................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
18 
 
FIGURE 6. 14 WCCO GENOTOXICITY. DNA DAMAGE IN C3A HEPATOCYTES AFTER 4-HOUR EXPOSURE IN THE 
PRESENCE AND ABSENCE OF FPG. DATA EXPRESSED AS AVERAGE % DNA IN TAIL  +/- SEM (N=3). PRISTINE 
WCCO NPS INCREASE THE PERCENTAGE OF DNA IN THE COMET TAIL. THERE IS NOT OBSERVABLE DOSE-
EFFECT AND ENHANCEMENT BY FPG. .......................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
FIGURE 6. 15 WCCO NPS INTERFERENCE. DNA DAMAGE RESULTS EXPRESSED AS DNA IN TAIL NORMALIZED BY 
POSITIVE CONTROL ON C3A HEPATOCYTES AFTER 4H EXPOSURE IN BOTH FPG POSITIVE (B) AND NEGATIVE 
(A) TREATMENTS. ....................................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. 
 
FIGURE A. 1 EVALUATION OF LPS CONTAMINATION BY LAL ASSAY. THE CONCENTRATION TESTED WAS 1 MG/ML 
FOR ALL NPS, EXCEPT MWCNTS (0.25 MG/ML), TIO2 ACID (0.06%) AND TIO2 GLYCOL (0.12%). ............... 22 
FIGURE A. 2 REPRESENTATION OF MACROPHAGE CELL LINE CYTOTOXICITY RESULTS AND BMD20 CALCULATION 
FOR THE NANOMATERIALS TESTED. .............................................................................................................. 24 
FIGURE A. 3 CYTOTOXICITY OF THE SOLUBLE FORMS OF CU AND CO ON MACROPHAGES. .................................... 25 
FIGURE A. 4 CYTOKINES RELEASE BY RAW264.7 MACROPHAGES AFTER EXPOSURE TO CUO NMS FOR 24H. ...... 27 
FIGURE A. 5 CYTOKINES RELEASE BY RAW264.7 MACROPHAGES AFTER EXPOSURE TO WCCO NMS FOR 24H. .. 28 
FIGURE A. 6 SUMMARY OF THE STIS ENDPOINTS. REPRESENTED THE DERIVED BMDS AND CONFIDENCE INTERVAL 
FOR ALL ENDPOINTS FOR WHICH A DOSE-RESPONSE WAS FOUND IN THE MAIN GROUPS. THE DOSE LEVELS ARE 
EXPRESSED AS 6-HOUR CONCENTRATION EQUIVALENTS IN MG/M3 ON A LOG SCALE. MP IS MACROPHAGES, 
PMN IS NEUTROPHILS................................................................................................................................... 30 
FIGURE A. 7 ORGAN BURDENS. ORGAN BURDENS (IN µG/G ORGAN DRY WEIGHT) WERE ASSESSED 1 DAY AFTER 
THE LAST EXPOSURE (DAY 6) AND AFTER A RECOVERY PERIOD OF 22 DAYS (DAY 28) IN CONTROL ANIMALS 
AND ANIMALS EXPOSED TO 11.6 MG/M3 CUO FOR 6 HOURS PER DAY, FOR 5 CONSECUTIVE DAYS IN A) LIVER, 
B) BLOOD, C) BONE MARROW, D) BRAIN, E) HEART, F) KIDNEY AND G) SPLEEN. THE DOSE LEVELS ARE 
EXPRESSED AS 6-HOUR CONCENTRATION EQUIVALENTS IN MG/M3. P < 0.05 COMPARED TO CONTROL. ......... 32 
FIGURE A. 8 CYTOKINE ANALYSIS. CYTOKINE CONCENTRATION IN 6 DAY LUNG AND LIVER HOMOGENATES FROM 
RATS INHALING PRISTINE, PEI AND ASC COATED CUO PARTICLES.  DATA IS NORMALISED TO THE AMOUNT 
OF PROTEIN PRESENT IN EACH HOMOGENATE AND REPRESENTS THE MEAN ±SEM OF THE NUMBER OF PG/MG 
PROTEIN FROM FIVE SEPARATE ANIMALS. ..................................................................................................... 36 
FIGURE A. 9 DNA METHYLATION ASSAY PERFORMED ON RAT LUNG TISSUE. RESULTS EXPRESSED AS AVERAGE % 
OF SEQUENCE METHYLATION AND RESPECTIVE SD. A) AVERAGE TOTAL METHYLATION AMONG THE 22 
GENES. NO SIGNIFICANT CHANGES WERE NOTED. B) LEVEL OF METHYLATION FOR THE FADD GENE, FOR 
WHICH SOME DEGREE OF STATISTICAL SIGNIFICANCE WAS FOUND. THE LETTERS INDICATE SIGNIFICANT 
DIFFERENCES (T-TEST, BONFERRONI-CORRECTED P-VALUE < 0.05). ............................................................. 37 
FIGURE A. 10HEATMAP FROM THE MICROARRAY EXPERIMENT PERFORMED ON LUNG TISSUE SAMPLES. THE MAP 
SHOWS THE DIFFERENCES IN MRNA LEVELS BETWEEN THE EXPERIMENTAL CONDITIONS. THE DATA 
PRESENTED HERE REFER TO  100 GENES ALLOCATED WITHIN SIGNIFICANTLY ACTIVATED BIOLOGICAL 
PATHWAYS ACCORDING TO KEGG PATHWAY ANALYSES (BENJAMINI-CORRECTED P <.0.05), MOSTLY 
RELATED TO CELL PROLIFERATION AND INFLAMMATION .............................................................................. 38 
FIGURE A. 11 HEATMAP DERIVED FROM INGENUITY PATHWAYS (IPA) ANALYSIS COMPARING THE FOUR 
EXPERIMENTAL CONDITIONS. THE DATA SET WAS CONTRASTED TO ALL AVAILABLE DATABASES, INCLUDING 
IN VIVO AND IN VITRO LUNG MODELS. THE THRESHOLD FOR ACCEPTANCE OF ACTIVATION/DEACTIVATION OF 
PATHWAYS WAS CONSIDERED TO BE P < 0.05, Z < -2 (DEACTIVATION) AND Z > 2 (ACTIVATION). ................ 39 
FIGURE A. 12 MICROGRAPHS FROM THE IHC-IF ANALYSES IN RAT LUNGS, USING THE ANTI-KI67 ANTIBODY AS A 
PROBE FOR CELL PROLIFERATION IN RAT ALVEOLAR EPITHELIA. A) CONTROL RATS. B) RATS EXPOSED TO 
HD FOR 5 CONSECUTIVE DAYS. NOTE ALVEOLAR EPITHELIAL HYPERPLASIA, INFILTRATION OF IMMUNE 
CELLS AND UPREGULATION OF THE KI67 PROTEIN (ARROWHEADS), STAINED GREEN/YELLOW, CONFIRMING 
CELL PROLIFERATION. COUNTERSTAIN: DAPI (BLUE). ................................................................................. 40 
FIGURE A. 13 CYTOKINE PROTEIN CONCENTRATIONS (µG/MG PROTEIN) PRESENT IN SELECTED TISSUES FROM RATS 
DOSED ORALLY WITH 16 AND 32MG/KG OF CUO AND SACRIFICED AT DAY 6 AFTER ORAL TREATMENT FOR 5 
CONSECUTIVE DAYS (DAYS 1-5). DATA REPRESENT THE MEAN±SEM OF EACH CYTOKINE DETECTED (µG/MG 
PROTEIN) AND REPRESENTS DATA FROM FOUR SEPARATE ANIMALS. ............................................................. 56 
FIGURE A. 14 GSH CONCENTRATION (TOTAL AND REDUCED FORMS) (µG/MG PROTEIN) PRESENT IN THE LIVER OF 
RATS DOSED ORALLY WITH 16, 32 AND 512MG/KG OF CUO AND 64 AND 128MG/KG OF CUCO3. ANIMALS 
WERE SACRIFICED AT DAY 6 AFTER ORAL TREATMENT FOR 5 CONSECUTIVE DAYS (DAYS 1-5). DATA 
REPRESENT THE MEAN±SEM OF GSH (µG/MG PROTEIN) AND REPRESENTS DATA FROM FOUR SEPARATE 
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Appendix 
 
 
Characterization of NPs and NMs 
 
Both the report on the characterisation of pristine nanomaterials for (eco)toxicological testing 
and the report on the characterisation of NOAA in biological samples from (eco)toxicity tests 
are available online at the following links: 
 
http://www.sun-fp7.eu/wp-content/uploads/2017/01/SUN_Deliverable_1.4.pdf 
 
http://www.sun-fp7.eu/wp-content/uploads/2017/01/SUN_Deliverable_1_5.pdf 
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Deliverable D 6.1 - Report on non-immune and immune cell responses to the 
SUN priority NOAA in terms of the acute cytotoxicity, inflammatory and 
genotoxic effects 
 
Endotoxin (LPS) detection 
 
The procedure followed the Nanotechnology Characterization Laboratory protocol (NCL 
Method STE-1.1) using the assay QCL-1000™ Endpoint Chromogenic LAL Assay (Lonza). 
All values obtained were below 0.5 EU/ml (Figure A.1), considered the maximum admissible 
limit for medical devices. Additionally, no interferences between the NM samples and the assay 
substrate were observed. 
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Figure A. 1 Evaluation of LPS contamination by LAL assay. The concentration tested was 1 mg/ml for all NPs, except 
MWCNTs (0.25 mg/ml), TiO2 acid (0.06%) and TiO2 glycol (0.12%). 
 
 
Cytotoxicity 
 
The cytotoxic potential of the nanomaterials was investigated using the Alamar Blue cell 
viability assay. Cells were exposed to increasing concentration of the nanomaterials (from 0 
µg/ml to 125 or 200 µg/ml) for 24h; the MWCNTs were tested up to 48h for macrophages. The 
results raw data were collected using the SUN Excel templates and were used to calculate the 
benchmark dose 20 (BMD20) and the EC50 for each NM by PROAST software.  
For the macrophage cell line, the cytotoxicity assessment showed a high toxicity (BMD20 ≤100 
µg/ml) for CuO, WCCo and SiO2, and a low toxicity (BMD20 >100 µg/ml) for MWCNTs, the 
pigment NMs and TiO2 (Table A.1 and Figure A.2). The most toxic NM was, however, CuO 
with the value of BMD20=25.50 µg/ml and EC50=40.97 µg/ml. Additionally, the salt forms of 
Cu and Co, CuCl2 and CoCl2 respectively were also tested using the same experimental design 
(Table A.1 and Figure A.3). 
 
 
 
Table A. 1 NPs and NMs cytotoxicity on macrophage. 
NOAA Time point 
BMD20 
(µg/ml) 
EC50 
(µg/ml) 
CuO_1_NP_SYN 24h 25.50 40.97 
CuCl2 24h 55.60 63.91 
24 
 
WCCo_1_NP_SYN 24h 48.10 98.08 
CoCl2 24h 32.70 58.54 
MWCNT_1_NP_SYN 24h 132 >200 
MWCNT_1_NP_SYN 48h >200 >200 
Pigment_1_NP_SYN 24h 123 >125 
Fe2O3_1_NP_SYN 24h >125 >125 
SiO2_1_NP_SYN 24h 63.70 103.3 
TiO2_1_SOL_MPG_SYN 24h >200 >200 
TiO2_2_SOL_HCl_SYN 24h >200 >200 
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Figure A. 2 Representation of macrophage cell line cytotoxicity results and BMD20 calculation for the nanomaterials tested. 
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Figure A. 3 Cytotoxicity of the soluble forms of Cu and Co on macrophages. 
 
 
 
Cytokine release 
 
The inflammatory response was evaluated using the Luminex assay in the supernatant of cells 
exposed to CuO, WCCo and MWCNTs. The measurements were performed after 24h of 
exposure to concentrations corresponding to BMD20x0.5, BMD20x1, and BMD20x2 except for 
MWCNTs which were tested only at the concentration of BMD20x0.5 and BMD20x1. The 
experimental setup included negative controls (culture medium only) and positive controls 
(cells exposed to 100 ng/ml of lipopolysaccharide, LPS). The possible interference of NMs 
with the cytokine detection was also evaluated. 
The selection of cytokines to be analyzed was based on previous in vivo data (provided by 
RIVM), in-house experience with similar studies and a literature search. Ten cytokines and 
chemokines were selected: TNF-α, IL-6, IL-1β, IL-10, IL-12, MCP-1 (MCAF; CCL2), MIP-
1β (CCL3), MIP-1α (CCL4), RANTES (CCL5), KC (IL-8, CXCL8). 
 
 
 
CuCl2 
(24h) 
CoCl2 
(24h) 
A B 
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The measurements in the supernatant after 24h of exposure to CuO showed an increase of TNF-
α and MCP-1 while the other cytokines were decreased compared with the control (Figure A.4). 
The exposure to WCCo induced an increase of TNF-α, IL-6 and IL-12 and a decrease of the 
other cytokines comparing with the control (Figure A.4). Two cytokines analyzed (KC and IL-
1β) could not be detected in any of the samples. The preliminary results obtained for MWCNTs 
showed an increase of the chemokine analyzed (MCP-1, MIP-1β and MIP-1α) but these need 
to be confirmed by additional measurements (data not shown). 
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Figure A. 4 Cytokines release by RAW264.7 macrophages after exposure to CuO NMs for 24h. 
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Figure A. 5 Cytokines release by RAW264.7 macrophages after exposure to WCCo NMs for 24h. 
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Conclusions  
 
The results showed that CuO and WCCo NMs displayed a high toxicity after 24h of exposure 
in both cell models, macrophages and hepatocytes, CuO being more toxic in comparison with 
WCCo. The RAW264.7 macrophages showed a higher sensitivity to WCCo NMs compared 
with the C3A hepatocytes. Further investigations to explain these observations will be 
necessary including evaluation of NM uptake by these cell lines. The cytotoxicity results were 
used to guide the experimental design of in vivo experiments in FP7-SUN while the cytokine 
release data was compared with the in vivo findings (histopathology, DNA methylation and 
gene expression) and integrated into the risk assessment process for nanomaterials in a later 
stage of the project. 
 
 
 
Deliverable D 6.3 - Report on molecular, histological, biochemical and epigenetic 
responses as well as information on biopersistence identified in the STIS with 
pristine and released/aged NOAA 
 
RIVM - Inhalation exposure 
 
Rats were exposed nose-only to a single exposure concentration, and by varying the exposure 
time, different dose levels were obtained (C x T protocol). The dose is expressed as 6 hour -
concentration equivalents of 0, 0.6, 2.4, 3.3, 6.3 and 13.2 mg/m3 CuO NPs, with a primary 
particle size of 10 9.2-14 nm and an MMAD of 1.5 µm. 
Twenty-four hours after a 5-day exposure, dose-dependent lung inflammation and cytotoxicity 
was observed. Histopathological examinations indicated alveolitis, bronchiolitis, vacuolation 
of the respiratory epithelium and emphysema in the lung starting at 2.4 mg/m3. After a recovery 
period of 22 days, limited inflammation was still observed, but only at the highest dose of 13.2 
mg/m3. The olfactory epithelium in the nose degenerated twenty-four hours after exposure to 
6.3 and 13.2 mg/m3, but this was restored after 22 days. No histopathological changes were 
detected in the brain, olfactory bulb, spleen, kidney and liver.  
In conclusion, a 5-day, 6-hour/day exposure equivalent to an aerosol of agglomerated CuO NPs 
resulted in a dose-dependent toxicity in rats, which almost completely resolved during a 3 -
week post-exposure period.  
The data for all endpoints measured were compared via the BMD calculated via PROAST.  
This allowed a ranking of the relative sensitivity of each endpoint to the inhaled CuO NP 
treatment (Figure A.5), with biochemical markers and inflammatory cell number in the 
bronchoalveolar lavage fluid providing to be the most sensitive indicators for lung toxicity. 
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Figure A. 6 Summary of the STIS endpoints. Represented the derived BMDs and confidence interval for all 
endpoints for which a dose-response was found in the main groups. The dose levels are expressed as 6-hour 
concentration equivalents in mg/m3 on a log scale. MP is macrophages, PMN is neutrophils. 
 
RIVM kinetics study  
 
NB. All of the figures and tables referred to in this section are included in the paper by Gosens 
et al. (2016). 
The blood, bone marrow, lungs, brain, liver, spleen, kidney, heart, testis and epididymis tissues 
were freeze-dried and sent ready for ICP-MS analyses for Cu content. The testis and epididymis 
were very fatty organs, and the freeze dry process did not work very well for those organs. 
Some organs were dried, but other were still wet and sticky. This gives problems in 
interpretation of the data expressed as dry organ weights. Therefore, the Cu content of testis 
and epididymis were not measured. 
Organ burdens were assessed 1 day after the last exposure (day 6) as well as after the recovery 
period (day 28) expressed in µg Cu/g dry tissue (supplementary figure 5, Gosens et al., 2016). 
The varied concentration equivalents resulted in a different Cu dose in the lung at day 6 (Figure 
3A). The measured lung burden was compared with the modelled burden at day 6 using MPPD 
software by the combined tracheobronchiolar and pulmonary deposition based on the actual 
aerosol concentration of 11.6 mg/m3 (highest exposure for the animals dedicated for burden 
analysis) and the aerosol characteristics as mentioned above (supplementary figure 4, Gosens 
et al 2016).  Using a similar calculation as described in the materials and methods section but 
including clearance assuming a retention half-time of 60 days, applicable for poorly soluble 
particles (Oberdorster, 2002), a lung burden of 0.2 mg at day 6 was estimated. The measured 
lung burden was linear with increasing equivalent concentration (Figure 3B, Gosens et al. 
2016). The measured total load for the highest exposed group, 1 day after the final exposure, 
was 0.085 mg per lung. This was only 43% of the modelled lung burden. Within the 22 day 
recovery period, Cu was cleared completely from the lung and levels returned to baseline 
(Figure 3A, Gosens et al. 2016). Therefore, the CuO NPs do not follow the kinetics of poorly 
soluble particles.  
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To examine the solubility of CuO NPs, dissolution was determined in Gamble’s solution (pH 
7.4) and artificial lysosomal fluid ALF (pH 4.5) (table 2, Gosens et al. 2016). At pH 7.4, around 
2% of CuO was present as Cu2+ ions. However, at a lower pH, representative of the internal 
milieu of phagocytizing cells, 60% of CuO NPs mass rapidly dissolved within 1 hour (table 2, 
Gosens et al 2016). During the dissolution measurements, the hydrodynamic diameter and ζ -
potential of the CuO NPs was determined by DLS and ELS, in both Gamble’s solution 
(supplementary table 2, Gosens et al. 2016) and ALF (supplementary table 3, Gosens et al. 
2016). In Gamble’s solution, particle agglomeration was observed, reaching approx. 1 µm, 
followed by sedimentation, due to the presence of salts, primarily NaCl and NaHCO3. After 24 
hours, no particle size distribution could be determined due to a low-intensity signal from the 
DLS. ζ-potential values suggested the high instability of the dispersions (-5±0.4 mV), 
confirming agglomeration and sedimentation of CuO NPs. In ALF, CuO NPs dissolved very 
quickly, and therefore the hydrodynamic particle size distribution could only be determined at 
time point 0, directly after preparing the suspensions. A bi-modal size distribution was 
observed at time point 0: 8% of CuO NPs had an average size of 48±8 nm, and 92% reached 
an average size of 231±51 nm. In this case, ζ-potential values could not be obtained due to the 
relatively rapid dissolution rate (from seconds to minutes), confirmed also by the intensity 
values of DLS (supplementary table 3, Gosens et al. 2016).  
No exposure-related increases above background Cu levels were observed in organs other than 
lungs, such as liver, blood, bone marrow, brain, heart, kidney and spleen (Figure A.6). A slight 
decrease in Cu levels was found in the liver after the recovery period. This is most probably 
related to a non-statistically significant increase in liver weight in the recovery group (data not 
shown).  
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Figure A. 7 Organ burdens. Organ burdens (in µg/g organ dry weight) were assessed 1 day after the last exposure 
(day 6) and after a recovery period of 22 days (day 28) in control animals and animals exposed to 11.6 mg/m3 
CuO for 6 hours per day, for 5 consecutive days in A) liver, B) blood, C) bone marrow, D) brain, E) heart, F) 
kidney and G) spleen. The dose levels are expressed as 6-hour concentration equivalents in mg/m3. P < 0.05 
compared to control. 
 
HWU Cytokine estimations in lung and liver homogenates  
 
The tissue from this study comprised lung and liver from rats inhaling different airborne mass 
concentrations of pristine CuO particles.  A control group of animals inhaled air only and 
tissues were obtained at day 6.  Each group consisted of five animals, but in some conditions, 
there were missing samples due to the tissue being used for other purposes.  
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Approximately 5mm x 5mm pieces of frozen lung or liver tissue obtained from the exposed 
animals were defrosted and placed in 1.5ml narrow Eppendorf tubes.  The homogenisation 
process was carried out on ice.  Two hundred and fifty microliters of lysis buffer (containing 
150mM NaCl, 50mM Tris buffer pH 8.0, 1% Triton and 1 Sigma antiprotease tablet) was added 
to each tube and the tissue finely chopped using surgical scissors.  Homogenisation was 
completed using a VWR VDI 12 hand held homogeniser (setting number 3) for 20 seconds.  
Samples were then rapidly frozen in liquid N2 and defrosted at room temperature after which 
they were sonicated for 20 seconds in a sonic bath.  Samples were centrifuged at 4500g for 4 
minutes at 4ºC and the supernatant transferred to clean Eppendorf tubes, labelled and stored at 
-80ºC until required. 
Homogenate samples were diluted 1:20 in PBS and the protein content measured using 
fluorescamine (1.5mg in 10mls DMSO).  A series of BSA standards ranging from 1000µg/ml 
to 0 µg/ml in PBS was prepared.  Twenty-five microliters of standard or diluted homogenate 
were pipetted into duplicate wells of a 96 well plate and 25µl of stock fluorescamine solution 
added to each well.  The plate was covered with foil and placed on a shaker for 2 minutes, after 
which the plate was read on a plate reader set to measure at 360nm excitation and 450nm.  The 
protein content of each sample was calculated using a linear regression obtained from the 
standard curve. 
The cytokine measurements were carried out using the Magpix (BioRad) technology.  
Cytokines of interest (IL-1α, IL-1β, IL-6, IL-12, IL-13, TNF-α and MIP-2) were selected, and 
a master mix of coated magnetic beads was prepared.  The beads were added to duplicate 
groups of wells on a black 96 well plate, and diluted tissue homogenates added.  A series of 
cytokine standards were included.  After incubation, the beads were washed and treated with 
detection antibody, followed by another series of washes.  Finally, PE-labelled streptavidin was 
added.  The fluorescence obtained in each well was measured using a Magpix plate reader, 
each cytokine of interested was detected in different channels of the, and the concentration was 
calculated using a four-parameter curve calculated from the standards. 
Data from the experiments were analysed using the Minitab statistical package.  Analysis of 
variance using a general linear model and Tukey’s post-test was used.  Significance was set at 
5%.  
Figure A.8 shows the concentration of each cytokine present in lung and liver tissue.  The 
cytokine concentration has been normalised to the protein content. Note that Figure 6 also 
contains data for the modified CuO which will be described and discussed in subsequent 
sections of the report. 
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Figure A. 8 Cytokine analysis. Cytokine concentration in 6 day lung and liver homogenates from rats inhaling 
pristine, PEI and ASC coated CuO particles.  Data is normalised to the amount of protein present in each 
homogenate and represents the mean ±SEM of the number of pg/mg protein from five separate animals.   
There was no detectable IL-6 or IL-13 in any of the lung homogenates.  For the pristine 
particles, there was no clear dose effect.  IL-1α was significantly increased at the 0.6, 3.3 and 
13.2 mg/m3 doses compared with the control.  This pattern was similar to IL-1β concentrations, 
although there was no significant increase at the 3.3 mg/m3 dose.  Both IL-12 and TNF-α 
showed a degree of variation and no statistically significant increase was observed at any 
concentration.  In the case of MIP-2, the cytokine level was significantly greater than the 
control at doses of 0.6, 3.3 and 13.2 mg/m3.  
Inhalation of pristine CuO particles did not cause any significant increase in any of the 
cytokines investigated in the liver at day 6.  However, at 6.3 and 13.2 mg/m3 particle 
concentrations, there was a significant reduction in the amount of IL-1β.  A similar profile with 
pristine particles was observed across all of the cytokines investigated, but there were no other 
significant effects.   
 
Karolinska Institutet and Health Canada epigenetics and transcriptomics 
 
KI performed epigenetic analyses on genomic DNA extracted from the lung samples supplied 
by RIVM using the AllPrep DNA/RNA Mini kit for animal tissue (Qiagen). Due to the nature 
of exposure, this organ was prioritised over the liver, for which samples were also received. 
The potential epigenetic effects of exposure to CuO NPs were addressed by analysing the levels 
of DNA methylation in the lungs exposed to the doses of 6.3 (low dose, LD) and 13.2 (high 
dose, HD) mg/m3 for five days and after the 21-day recovery. For the purpose, a panel of 22 
inflammation-related genes was selected for analysis. It should be noted that genome-wide 
DNA methylation array is not readily available for studies on rat tissues, and, moreover, the 
approach would be prohibitively expensive. Thus, for our study, the EpiTect Methyl II PCR 
Array was used, coupled with the Epitect Methyl II DNA restriction kit (Qiagen). The assay 
consists of a qRT-PCR array for the target genes, following extraction of total DNA, and is 
based on the hindered transcription of methylated genes. The choice of the panel of genes was 
based on the high relevance of inflammation occurring as a result of exposure, as explained 
above. However, the levels of gene methylation were overall low (typically < 1%) for all genes 
(Figure A.9, A), and highly variable, accounting for no significant differences between any 
experimental treatment, albeit a trend to reduce the methylation in animals exposed to HD for 
five days. This could, nonetheless, relate to the increased levels of inflammation observed 
histopathologically in the lungs of these rats. Individually among the genes that were studied, 
only Fas-associated death domain (FADD) yielded a significant difference towards the 
controls, in animals exposed to LD for five days, relatively to controls (Figure A.9).  
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Figure A. 9 DNA methylation assay performed on rat lung tissue. Results expressed as average % of 
sequence methylation and respective SD. A) Average total methylation among the 22 genes. No 
significant changes were noted. B) Level of methylation for the FADD gene, for which some degree of 
statistical significance was found. The letters indicate significant differences (t-test, Bonferroni-
corrected p-value < 0.05). 
 
These findings indicated that a relation between epigenetic regulation of gene expression and 
the reported endpoints related to the inflammatory response in the exposed animals could not 
be shown, as far as could be ascertained based on the panel of selected inflammation-related 
genes. Therefore, the corresponding analysis was not conducted on liver samples. Instead, 
following detailed discussion within WP6 and with the scientific advisory board member, Dr 
Sabina Halappanavar (Health Canada = HC), the decision was taken to move from epigenetics 
analyses to gene expression analyses, or transcriptomics. Dr Halappanavar thus volunteered to 
perform microarray-based transcriptomics analyses at no cost, on the samples from WP6. To 
this end, RIVM provided samples from rat lung tissues to KI, and a protocol was developed at 
KI for extraction of RNA followed by shipment of samples to HC. Considerable care was taken 
to ensure that adequate protocols were established to extract RNA samples of high quality for 
the microarray experiments. The quality of RNAs was assessed through RIN (RNA Integrity 
Number), which was found to be > 7, as recommended for the purpose. As previous, lung was 
selected as a priority for being the apical entry organ of toxicants upon inhalation. The 
microarray study was based on the Agilent Rat Oligonucleotide Platform. Following 
microarray analysis (at HC), data were transferred to KI and downstream bioinformatics 
analysis of the data was performed at KI. The results showed that exposure to HD for 5 days 
yielded the most significant changes in gene expression, accounting for about significantly 
changed mRNA of about 1,000 genes (considering a minimum fold change ratio of 2, with 
FDR-corrected p < 0.05), the majority of which, up-regulated (Figure A.10). In contrast, 
samples collected after the recovery period (see above) yielded only < 20 dysregulated genes, 
thus indicating the return to levels similar to controls, in agreement with the work described 
above. In-depth bioinformatics including pathway analyses (such as KEGG and Ingenuity 
Pathway Analysis, IPA), showed that most genes related to inflammation and cell proliferation 
in exposed animals, again in accordance with the previous results and seemingly in a dose-
response manner, albeit reversible after the recovery period.  
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Figure A. 10Heatmap from the microarray experiment performed on lung tissue samples. The map shows the differences in 
mRNA levels between the experimental conditions. The data presented here refer to  100 genes allocated within significantly 
activated biological pathways according to KEGG pathway analyses (Benjamini-corrected p <.0.05), mostly related to cell 
proliferation and inflammation 
. 
 
Furthermore, detailed pathway analyses were done using the IPA software through a 
comparative approach between all experimental conditions. The results confirmed the 
relevance of inflammation and cell proliferation pathways as a response to insult in LD and 
HD-subjected animals (Figure 8.11). No significantly changed, i.e., activated or deactivated, 
pathways were found after recovery, indicating a reversal of effects back to the level seen in 
control animals. In sum, the study provided molecular evidence for the reversibility of effects. 
In addition, these studies also showed that also the short-term exposure regimen resulted in 
changes as a consequence of the association between inflammation and hyperplasia in lung 
bronchoalveolar tissue, which is regarded as a potential pre-neoplastic condition. No evident 
correlations were found between the epigenetics results and transcriptomics results (data not 
shown). Overall, the transcriptomics studies have added further insight regarding molecular 
events following short-term inhalation exposure to CuO NPs. 
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Figure A. 11 Heatmap derived from Ingenuity Pathways (IPA) analysis comparing the four experimental conditions. The data 
set was contrasted to all available databases, including in vivo and in vitro lung models. The threshold for acceptance of  
activation/deactivation of pathways was considered to be p < 0.05, Z < -2 (deactivation) and Z > 2 (activation). 
 
 
The abovementioned findings from the microarray experiments were then verified 
immunohistochemically by KI using fluorescent-labelled secondary antibodies (IHC-IF) from 
paraffin-embedded samples (supplied by RIVM) using several probes, such as the anti-Ki67 
antibody for the localization of proliferating cells, using fluorescence microscopy (IF) (Figure 
A.12). Both the microarray experiments and IHC-IF analysis state inflammation and alveolar 
epithelial cell proliferation as the main changes caused by exposure, albeit reversible after 
removal of a challenge. These effects occurred in an obvious dose-response manner and 
confirmed that exposure to CuO NPs by inhalation yield both epithelial cell proliferation and 
inflammation. A manuscript is currently being finalized by KI in collaboration with HC and 
RIVM. 
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Figure A. 12 Micrographs from the IHC-IF analyses in rat lungs, using the anti-Ki67 antibody as a probe for cell proliferation 
in rat alveolar epithelia. A) Control rats. B) Rats exposed to HD for 5 consecutive days. Note alveolar epithelial hyperplasia, 
infiltration of immune cells and upregulation of the Ki67 protein (arrowheads), stained green/yellow, confirming cell 
proliferation. Counterstain: DAPI (blue). 
 
 
 
Second STIS - Safety by Design Polyethylenimine and Ascorbate Modified CuO 
 
The original plan had been to use fragmented particles (FP) from a polymer composite 
including CuO (WP 5). However this was unsuccessful due to the soft nature of the composite. 
Since WP7 was also making modified CuO in order to improve their safety by design, the 
modified CuO were considered for the inhalation study.   
 
Initially, discussions were held with WP7 partners to consider the range of surface 
modifications under consideration.  The toxicology partners of WP6 suggested that ascorbate 
(ASC) might we worth considering as a novel surface modification.  Ascorbate is negatively 
charged and so should improve the suspension stability, but in addition, ascorbate is an 
antioxidant found naturally in the body, including in lung lining fluid.  The natural occurrence 
of ascorbate and its antioxidant properties should help to mitigate any NP (or even Cu2+) 
induced toxicity.  The partners of WP7 utilised this idea to successfully generate the ascorbate 
coating.  In addition, they provided citrate, polyethylenimine coating (PEI) and 
polyvinylpyrrolidone PVP coated CuO NP (D7.1). 
 
KI and HWU in vitro studies to guide the in vivo study design 
 
As a step to prepare the STIS bioassays with pristine CuO NPs, this ENM was tested in vitro 
using the RAW264.7 macrophage-like cell line (KI) and C3A hepatocytes (HWU), as 
described in Deliverable 6.1. This was followed by a series of assays with the same cell lines, 
also conducted at KI and at HWU to test the cytotoxicity of the different surface-modified CuO 
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NPs, namely with the anionic sodium citrate (CIT), sodium ascorbate (ASC); the neutral 
polyvinylpyrrolidone (PVP) and the cationic polyethylenimine (PEI). The results were 
evaluated using the benchmark dose approach using the PROAST software package for R and 
data are reported in Table A.2 (below). While differences could be discerned for the different 
modified CuO NPs, the cytotoxicity was not entirely resolved, as the modified (capped) NPs 
retained their toxicity (the particles were not “non-cytotoxic”). Nevertheless, ASC-modified 
NPs were the least cytotoxic for both cell lines (see BMD20 values in Table A.2). Cytotoxicity 
of modified NPs to RAW264.7 macrophages was ranked as PEI-capped > uncapped NPs > 
PVP-capped > CIT-capped > ASC-capped. The findings were similar to the results for C3A 
hepatocytes, except that PVP-coated NPs were found to be the most cytotoxic.  
Furthermore, the effects of capping agents on particle dissolution were addressed by KI using 
RAW264.7 macrophages, suggesting that only marginal differences occurred between the 
distinct synthesised materials and only for a brief period, since after 24 h the dissolution rates 
of NPs in DMEM were similar ( 66%). Overall, the cytotoxicity of modified CuO NPs tested 
with this in vitro model seems to result from the interaction between NP and capping agent 
toxicity and neither by Cu burden per se or NP internalization, which was verified by ICP-MS 
and transmission electron microscopy. Altogether, this information was used to guide the 
subsequent in vivo assays, as previously decided by the teams involved. A manuscript is 
currently being produced with the in vitro data on surface-modified CuO NPs, in collaboration 
with partners from WP7, who manufactured and supplied the tested NPs. 
 
 
Table A. 2 Benchmark dose estimates (BMD20), in μg/ml, and respective 95% upper and lower bound obtained from in vitro 
assays with macrophages (RAW267.4) and hepatocytes (C3A). 
Capping 
agent RAW267.4 
 C3A 
Uncapped 2.74 (2.14 - 3.42)  18.7 (16.81 - 20.64) 
Citrate 10.60 (9.03 - 12.24)  25.7 (23.07 - 28.58) 
Ascorbate 11.70 (9.23 - 13.48)  64.8 (59.02 - 70.81) 
PVP 5.06 (4.34 - 5.81)  16.6 (14.77 - 18.55) 
PEI 1.65 (1.12 - 2.33)  20.4 (18.43 - 22.36) 
 
Thus, on the basis of the in vitro results reported above, CuO NP modified with a PEI 
(positively) charged and ASC treatment (resulting in a negative charge) were tested in the 
subsequent STIS. This also allowed the relative toxicity of positive and negatively charged 
CuO NPs compared to the pristine material to be addressed. 
The hypothesis was that the positively charged particles would render the particles more toxic 
compared to the unmodified particles, while the negative charged coating will protect against 
toxic effects.  A positively charged particle could be more easily recognized by the immune 
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system (macrophages), while the ascorbate coating could reduce the Cu2+ ions (that are linked 
to the toxicity) to Cu0, or the ascorbate forms a complex with the Cu2+ ions or both. 
The test item-related toxicological relevant morphologic alterations following the 
administration of CuO nanoparticles (positively coated with PEI or negatively coated with 
ASC) for 5 days to rats were present mainly in the lung and its draining lymph node, the 
mediastinal lymph node. Findings consisted of interstitial/alveolar inflammation and 
hypertrophy/hyperplasia of bronchioles/alveoli with accompanying alveolar (cellular) debris 
in the lung and paracortical histiocytosis in the mediastinal lymph node. Although all treatment 
groups were affected, the findings starting at a dose of 1.8 mg/kg3 CuO-PEI and 2.3 mg/ kg3 
CuO-ASC were considered to be adverse, based on the nature and severity of the findings. 
After 21 days, recovery was ongoing since the number of alveolar macrophages was still 
slightly increased at all doses of both CuO-PEI and CuO-ASC, and two males treated at 17.3 
mg/kg3 still showed minimal bronchiolar hypertrophy/hyperplasia.   
All data have been collected and entered in the data transfer sheets (Table A.3). BMD analyses 
are in progress. Initial considerations of the data suggest that like the pristine CuO NP, both of 
the modified CuO NP induce a significant inflammation at day 6.  For the PEI coated NPs, a 
residue of inflammatory cell accumulation remains at day 28; again this is comparable to the 
pristine CuO NP.  For the ASC modified CuO NPs, there appears to be no inflammatory cell 
accumulation at day 28 for any exposure concentration, suggesting that the ASC may have 
provided some protection preventing the inflammatory effects persisting to day 28.  This needs 
to be verified via statistical analysis of the data. 
 
 
Table A. 3 The result of cell differentials in BALF showing dose-dependent effects. 
 
  
DAY 6 
    
abs. aantal (x 
10
6
/ml pellet) 
    
             
      
celconc.  Macro- Macrof.  Neutrof. Eosinof. Lymfoc. Monoc. 
    
n 
 
(10
6
/ml 
pellet) fagen meerk. granuloc. granuloc. 
  
             Groep 1, clean air 0 mg/m3, 3h 5 gemid. 0,488 0,458 0,003 0,021 0,001 0,005 0,000 
     
sd 0,191 0,174 0,002 0,018 0,002 0,004 0,000 
             Groep 2, CuO PEI 0.6 mg/m3, 7 min. 4/3 gemid. 0,805 0,464 0,008 0,127 0,000 0,004 0,000 
     
sd 0,158 0,318 0,008 0,102 0,001 0,003 0,000 
             Groep 3, CuO PEI 1.7 mg/m3, 20 min. 5 gemid. 2,848 0,337 0,022 2,442 0,008 0,037 0,002 
     
sd 0,883 0,277 0,023 0,944 0,005 0,060 0,005 
             Groep 4, CuO PEI 5.0 mg/m3, 1h. 5 gemid. 6,260 1,095 0,025 4,742 0,009 0,386 0,003 
     
sd 0,755 0,403 0,034 0,811 0,008 0,195 0,007 
             Groep 5, CuO PEI 15 mg/m3, 3h. 5 gemid. 12,481 1,867 0,000 10,233 0,002 0,378 0,000 
     
sd 5,342 1,056 0,000 4,643 0,004 0,287 0,000 
             Groep 6, CuO ACS 0.77 mg/m3, 7 min. 5 gemid. 0,941 0,453 0,005 0,456 0,006 0,020 0,000 
     
sd 0,302 0,404 0,005 0,184 0,003 0,026 0,000 
             Groep 7, CuO ACS 2.2 mg/m3, 20 min. 5/4 gemid. 3,145 0,662 0,026 2,122 0,008 0,149 0,051 
     
sd 0,983 0,122 0,015 0,888 0,012 0,123 0,096 
             Groep 8, CuO ACS 6.7 mg/m3, 1 h. 4 gemid. 6,786 1,361 0,014 4,847 0,019 0,472 0,073 
     
sd 2,160 0,650 0,010 1,409 0,018 0,189 0,046 
             Groep 9, CuO ACS 20 mg/m3, 3 h. 5 gemid. 14,814 2,444 0,021 11,392 0,017 0,816 0,123 
     
sd 3,901 1,071 0,036 3,702 0,024 0,311 0,119 
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HWU Cytokine estimations in lung and liver homogenates  
 
Again, there was no detectable IL-6 or IL-13 in any of the lung homogenates.  With both 
modified particle types, there was a clearer effect of dose of particles compared with the effects 
observed with the pristine particles.  The PEI coated NP produced an increase in IL-1α at the 
1.8 mg/m3 dose compared with the control and a significant increase in IL-1β at the 0.6 and 
17.3 mg/m3 doses.  Similarly, there was an increase in MIP-2 at the highest dose of 17.3 mg/m3.  
No significant increase in IL-12 or TNF-α was observed after PEI modified CuO particle 
inhalation at any concentration.  The ASC modified CuO NP did not cause any increased 
cytokine release in the lung except for MIP-2, which was significantly greater than the control 
at the dose of 21.8 mg/m3.  Therefore, in the lung, the ASC modification appeared to dampen 
the pro-inflammatory cytokine signalling compared to the pristine and PEI modifications. 
Inhalation of pristine CuO particles did not cause any significant increase in any of the 
cytokines investigated in liver tissue.  With the modified particles, there was only a significant 
increase in IL-1β for the PEI coating at 1.8 mg/m3 and for ASC at 0.8 and 2.3 mg/m3. 
 
KI – DNA methylation and microarray analysis 
 
As stated above, the findings from the epigenetics study within the previous STIS experiment 
revealed little correlation between DNA methylation and inflammation or other relevant 
endpoints. Therefore, it has been decided to replace these analyses with a microarray-based 
   
DAY 27 
    
abs. aantal (x 
10
6
/ml pellet) 
    
      
celconc.  Macro- Macrof.  Neutrof. Eosinof. Lymfoc. Monoc. 
    
n 
 
(10
6
/ml 
pellet) fagen meerk. granuloc. granuloc. 
  
             Groep 1, clean air 0 mg/m3, 3h 5 gemid. 0,508 0,439 0,008 0,041 0,001 0,020 0,000 
     
sd 0,093 0,137 0,006 0,048 0,001 0,032 0,000 
             Groep 2, CuO PEI 0.6 mg/m3, 7 min. 4 gemid. 0,413 0,352 0,011 0,043 0,000 0,007 0,000 
     
sd 0,077 0,105 0,001 0,028 0,001 0,004 0,000 
             Groep 3, CuO PEI 1.7 mg/m3, 20 min. 5 gemid. 0,523 0,455 0,004 0,051 0,000 0,013 0,000 
     
sd 0,140 0,113 0,004 0,051 0,000 0,008 0,000 
             Groep 4, CuO PEI 5.0 mg/m3, 1h. 5 gemid. 0,694 0,646 0,016 0,022 0,000 0,010 0,000 
     
sd 0,274 0,286 0,009 0,028 0,000 0,006 0,000 
             Groep 5, CuO PEI 15 mg/m3, 3h. 5 gemid. 0,463 0,388 0,009 0,056 0,000 0,011 0,000 
     
sd 0,187 0,182 0,006 0,100 0,000 0,013 0,000 
             Groep 6, CuO ACS 0.77 mg/m3, 7 min. 5 gemid. 0,758 0,670 0,011 0,062 0,001 0,014 0,000 
     
sd 0,130 0,116 0,006 0,052 0,001 0,011 0,000 
             Groep 7, CuO ACS 2.2 mg/m3, 20 min. 4 gemid. 0,604 0,568 0,014 0,017 0,000 0,005 0,000 
     
sd 0,237 0,235 0,008 0,012 0,000 0,004 0,000 
             Groep 8, CuO ACS 6.7 mg/m3, 1 h. 5 gemid. 0,525 0,497 0,021 0,004 0,000 0,004 0,000 
     
sd 0,139 0,136 0,009 0,003 0,000 0,002 0,000 
             Groep 9, CuO ACS 20 mg/m3, 3 h. 5 gemid. 0,487 0,458 0,016 0,005 0,000 0,008 0,000 
     
sd 0,158 0,158 0,009 0,003 0,000 0,006 0,000 
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“omics” study. As before, RIVM will supply the samples, KI will extract RNA following 
established protocols and will supply the samples to HC for microarray analysis (at no cost). 
The results of the microarray study are anticipated in June 2016 and will be followed by 
detailed bioinformatics analysis, performed at KI, and follow-up studies will be considered as 
needed.  
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Deliverable D 6.4 - Report on molecular, histological, biochemical and epigenetic 
responses as well as information on biopersistence identified in the STOS with 
pristine and released/aged NOAA 
 
Similar to the short-term inhalation study (STIS) in Deliverable 6.3 an oral study was 
developed to investigate possible toxic effects after short-term oral exposure. Based on the gap 
analysis as performed in WP1 of the SUN project CuO was the first nanomaterial (NM) 
investigated in this short-term oral study (STOS).  CuO is used as a wood preservative, and so 
oral exposure is possible by hand to mouth contact. For a second NM, one of the industrial 
partners suggested that CuCO3 nanomaterials would be a useful comparison with CuO as it is 
also widely used in wood preservatives.  Therefore, as a second NM CuCO3 was selected to 
perform a STOS for comparison. Both for CuO and CuCO3 oral exposure is deemed to be an 
important potential route of exposure.  
The aim of these studies was to evaluate whether 5 days oral exposure could be indicative for 
(sub)acute toxicity. In addition, the aim was to evaluate whether already after 5 days of 
exposure target organs can be identified for further in-depth study in follow-up repeated dose 
toxicity studies. 
 
Short-Term Oral Study (STOS) 
 
Experimental design - Male rats (RjHan:WI, bred Specific Pathogen Free, barrier maintained 
during the experiment) of 8-9 weeks old were obtained from Janvier Labs (Le Genest-Saint-
Isle, Saint Berthevin , France). The animals were treated on five consecutive days (days 1 - 5), 
and an autopsy was performed 24 hours after the last oral administration (day 6). In addition, 
a recovery period of 3 weeks was included in the experiments to evaluate recuperation or 
possible persistence of the nanomaterials in the body and ongoing pathology. An autopsy of 
the recovery groups was performed after a three weeks recovery period at day 26. 
For CuO initial doses were selected based on literature information (see below). A pilot study 
was performed with a high 64 mg/kg dose (day 1-5 daily). For CuCO3 a pilot study was 
performed to determine the starting dose in the STOS. One animal was treated orally with a 
single dose of CuCO3. If no toxicity was observed the dose was increased in the next animal 
until a toxic response was noted (OECD 425, 2008, OECD, Paris, France). When a single 
animal showed a toxic response additionally, 4 animals were administered the same dose. The 
highest dose chosen for the CuO was 512 mg/kg and for CuCO3 128 mg/kg. 
Exposure - CuO NM was orally administered by gavage using the following exposure doses:  
vehicle control, 1, 2, 4, 8, 16, 32, mg/kg body weight (b.w.) and a pilot study with 64 mg/kg 
b.w. The doses were chosen based on information in the literature of soluble non nano CuSO4 
which indicated a no observed adverse effect level (NOAEL) of 16.3 mg/kg (Hébert C.D. 
1993). The dose was administered as 0.1 ml per 20 g (1 ml per 200 g). In an additional study, 
one group of animals (n=4) was treated with a high dose of 512 mg/kg b.w. Information on 
copper published by the EU-RAR is presented on the ECHA website 
(http://echa.europa.eu/copper-voluntary-risk-assessment-reports). 
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CuO and CuCO3 nanoparticle dispersions were prepared starting with CuO powder and CuCO3 
liquid. Milli-Q water was used for further dispersion and/or dilution.  After dispersion, the CuO 
and CuCO3 nanoparticle dispersions were sonicated for 16 minutes in a water bath (Elmasonic 
S100) at room temperature to optimize dispersion quality. 
Before each administration, the nanoparticle dispersion was evaluated by CPS Disc 
Centrifuge™ (CPS Instruments Europe, Oosterhout, The Netherlands) to determine 
nanoparticle size and size distribution.  Both the CuO and the CuCO3 dispersions remained 
stable up to 24 and 72 hours, respectively, after preparation of the dispersion.  
Pathology - Potential toxicological effects of 5 days oral administration of CuO and CuCO3 
was evaluated 24 hours after the last administration (indicated with day 6 in the tables/figures). 
In addition, a recovery period of three weeks was included to evaluate possible recovery from 
toxic insults present after the treatment at day 6 (indicated as day 26). Animals were killed by 
exsanguination from the abdominal aorta during anaesthesia by isoflurane (3.5% in oxygen) 
inhalation.  General post-mortem examinations were performed on all animals. At the time of 
necropsy, the following tissues and organs were collected: Heart, Lung, Thymus, Liver, Spleen, 
Kidney, Testis (unilateral), Brain, Mesenteric lymph node, Adrenal glands, Pancreas, Prostate, 
Seminal vesicles, Epididymides, Thyroid gland, Skeletal muscle -quadriceps, Stomach, 
Duodenum, Jejunum, Ileum, Peyer’s patches, Cecum, colon, rectum, Skin, Popliteal lymph 
node, femur with bone marrow, Bone with bone marrow, and Peripheral Nerve.  
Microscopic examination of routinely prepared hematoxylin-eosin stained paraffin sections 
was performed on heart, lungs, thymus, stomach, duodenum, jejunum, ileum, Peyer’s patches, 
cecum, colon, rectum, liver, spleen, mesenteric lymph nodes, kidneys, adrenal glands, brain, 
testis (unilateral), femur with bone marrow of animals given in the study design table above. 
In addition, macroscopic findings were prepared and examined. Investigated were all control 
groups and 32, 64 and 512 mg/kg CuO treated animals. For CuCO3 treated animals the 
following doses were evaluated: controls and 32, 128 mg/kg CuCO3. The animal data and 
macroscopic lung findings were manually entered into the computer system PathData®. 
Stained histologic sections were examined by light microscopy, and the microscopic findings 
were recorded using on-line input under pathology number 41532 JOL.  
Severity grades were assigned to non-neoplastic histopathologic diagnoses, as presented below. 
Severity grades were assigned based on the severity of alterations in the examined histologic 
sections and may not reflect the overall severity of the pathologic process in the entire tissue, 
organ, or animal. Histopathological changes were described according to distribution, severity 
and morphological character. Severity scores for histopathology were assigned as follows:  
Present Finding present, grading not scored. 
Grade 1  Minimal/very few/very small. 
Grade 2  Slight/few/small. 
Grade 3  Moderate/moderate number/moderate size. 
Grade 4 Marked/many/large. 
Grade 5 Massive/extensive number/extensive size. 
N.A.D.  No Abnormality Detected 
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Haematology - Blood was collected in EDTA-coated tubes. Haematological parameters 
included white blood cell (WBC) count, red blood cell (RBC) count, haemoglobin (Hb), 
haematocrit (Ht), mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCHC), 
and platelet (PLT) count.  All haematology parameters in the blood samples were determined 
in an Advia 120 Hematology Analyzer (Siemens Health Care, Germany) according to the 
manufacturer’s instructions.  In addition, blood smears were prepared for visual evaluation 
depending on the results obtained with the haematology analyser. 
Bone marrow - Cells were collected by flushing 4 ml Impuls Cytometer Fluid through the left 
femur. The concentration of nucleated cells was determined in a Coulter Counter. 
Clinical chemistry - After collection of blood serum and storage at -20o C the following 
parameters were determined: albumin (ALB), alkaline phosphatase (ALP), alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase 
(GGT), amylase (AMY), creatinin kinase (CK), lactate dehydrogenase (LDH), sodium (Na), 
potassium (K), glucose (GLU), urea, creatinin (CRE), cholesterol (CHOL) and total protein 
(TP).  All clinical chemistry parameters in the serum samples were determined in an automatic 
analyser Unicel DxC 800 Synchron Clinical Systems (Beckman Coulter Nederland B.V., 
Woerden, The Netherlands). 
Cytokine protein content - Cytokine protein content was determined in various tissues from 
animals dosed orally with CuO or CuCO3. Tissues from 5-day dosed animals previously snap 
frozen in liquid nitrogen and stored at -200oC were defrosted prior to extraction.    The tissue 
was homogenised in an extraction buffer (as previously described for the inhalation study) and 
the protein content estimated as before (fluorescamine assay).  The cytokine concentration of 
the tissue extracts was determined as previously described using a Biorad Magpix system.  
Treatments consisted of CuO at doses of 16 and 32mg/kg, and CuCO3 at doses of 8 to 
128mg/kg. The tissues examined included stomach, ileum, duodenum, colon and liver.  The 
panel of cytokines consisted of IL-1α, IL-1β, IL-6, IL-12, IL-13 and TNF-α.  Animals were 
sacrificed at day 6 post dosing the animals during days 1-5 (i.e. 24 hours after the last oral 
administration).   
GSH in liver tissue from animals dosed orally with CuO or CuCO3 - Liver tissue from animals 
dosed as described above were homogenised as previously described for the inhalation study.  
The doses examined for the oral treatments included 64 and 128mg/kg CuCO3.  The CuO 
exposures consisted of doses at 16 and 32mg/kg but included a dose of 512mg/kg which was a 
dose included as a single high dose investigation.  The animals from this treatment were 
sacrificed at day 6 after treatment for 5 consecutive days (days 1-5). 
 
Results: CuO - General toxicity 
 
Assuming that the CuO would be dissolved in the acid environment of the stomach, a starting 
dose was selected based on the literature for dissolved CuSO4. The no observed adverse effect 
level (NOAEL) for CuSO4 was reported to be 16.3 mg/kg (RAR-ECHA).  A pilot study was 
conducted with 2 animals with a dose of 64 mg/kg. As this dose was well tolerated a dose 
response study was conducted with the highest dose of 32 mg/kg.  
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During the study, no signs of toxicity were noted, and there were no premature deaths in the 
study. There were no test item related findings at the macroscopic observation level at autopsy. 
For the extra group of animals treated with 512 mg/kg some indications for toxicity were 
observed. One animal showed some weight loss after two days of treatment and diarrhoea after 
three administrations. After four administrations two animals showed diarrhoea. 
Between the start of the exposure and autopsy, no loss in body weight was observed for CuO 
treated animals. For the doses evaluated up to 32 mg/kg no effect on body or organ weights 
was noted either at day 6 or day 26 (Table A.4 and 5).  
Table 1, A. Body and organ weight in male rats after 5 days consecutive oral administration of CuO.  At day 6 (24 hours after 
the last administration). 
Table A. 4. Body and organ weight in male rats after 5 days consecutive oral administration of CuO.  At day 6 (24 hours after 
the last administration). 
 
CuO         Pilot 
Study  
 Extra 
Study 
Dose  0 
mg/kg 
1 
mg/kg 
2 
mg/kg 
4 
mg/kg 
8 
mg/kg 
16 
mg/kg 
32 
mg/kg 
 64 
mg/kg 
 512 
mg/kga 
            
Body 
weight (g) 
275 ± 
8 
275 ± 
25 
292 ±9 310 ± 
46 
288 ±8 290 ± 7 280 ± 
23 
 288 ± 
4  
 334 ± 
43 
            
Lung 1.30 ± 
0.12 
1.33 ± 
0.10 
1.37 ± 
0.09 
1.53 ± 
0.09 
(3) 
1.53 ± 
0.08 
1.39 ± 
0.08 
1.35 ± 
0.10 
 1.29 
(1) 
 1.48 ± 
0.09 
Heart 0.881 
± 0.02 
0.938 
± 0.06 
0.957 
± 0.02 
0.934 
± 0.06 
0.945 
± 0.02 
0.976 ± 
0.03 
0.931 
± 0.06 
 0.934 
± 0.08  
 1.097 
± 0.16 
Liver 10.67 
± 0.52 
11.00 
± 0.47 
(3) 
11.19 
± 0.62 
11.01 
± 0.63 
11.22 
± 0.39 
10.52 
±0.80 
10.89 
± 1.14 
 11.01 
± 0.19  
 12.06 
± 2.21 
Kidney 
(L+R) 
2.18 ± 
0.08 
2.28 ± 
0.14 
(3) 
2.31 ± 
0.10 
2.22 ± 
0.18 
2.33 ± 
0.06 
2.33 ± 
0.09 
2.14 ± 
0.26 
 2.18 ± 
0.08  
 2.25 ± 
0.25 
Spleen 0.50 ± 
0.04 
0.50 ± 
0.04 
0.53 ± 
0.03 
0.52 ± 
0.04 
0.53 
±0.03 
0.54 ± 
0.03 
0.54 ± 
0.04 
 0.51 ± 
0.06  
 0.855 
± 0.22 
Thymus 0.503 
± 0.04 
0.537 
± 0.09 
0.552 
± 0.04 
0.591 
± 0.02 
0.544 
± 0.04 
(3) 
0.530 
±0.07 
0.527 
± 0.06 
 0.478 
± 0.03  
 0.526 
± 0.21 
Mesenteric 
Lymph 
Node 
0.126 
± 0.01 
0.157 
± 0.05 
0.161 
± 0.03 
0.154 
± 0.02 
0.144 
± 0.02 
0.164 ± 
0.03 
0.155 
± 0.02 
 0.125 
± 0.02  
 0.263 
± 0.07 
Testes 
(L+R) 
2.66 ± 
0.18 
2.50 
±0.64 
2.83 ± 
0.11 
2.93 ± 
0.10 
2.71 ± 
0.22 
2.80 ± 
0.11 
2.78 ± 
0.14 
 2.79 ± 
0.06  
 3.31 ± 
0.30 
Brain 2.00 ± 
0.03 
2.03 ± 
0.01 
20.6 ± 
0.02 
2.02 ± 
0.03 
2.04 
±0.04 
2.07 ± 
0.04(3) 
20.3 ± 
0.06 
 2.06 
(1) 
 2.11 ± 
0.03 
Adrenals 0.032 
± 
0.001 
0.034 
± 
0.005 
0.037 
± 
0.003 
0.037 
± 
0.002 
0.039 
± 
0.004 
(2) 
0.037 ± 
0.003 
0.039 
± 
0.003 
 -  0.058 
± 
0.005 
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Haematology and Clinical chemistry - At one day after the last treatment the data indicated 
effects on the immune system as the total white blood cell (WBC) count was decreased (Table 
A.6). There was an apparent increase in the percentage of neutrophilic granulocytes in the 
blood. This increase in the percentage of neutrophils did not actually represent an increase in 
an absolute number of neutrophilic granulocytes. Instead these remained static as the absolute 
total WBC number decreased. In addition, in the animals treated with 64 mg/kg CuO some red 
blood cell parameters (the number of red blood cells, haemoglobin content, and haematocrit) 
were decreased. At day 21 after treatment (day 26) all white and red blood cell parameters were 
similar to the values of the control vehicle-treated animals (Table A.7). There was no treatment-
related effect in the cellularity of the bone marrow after treatment with CuO nanoparticles 
(Table A.8). 
 
CuO        
Dose  0 
mg/kg 
1 
mg/kg 
2 
mg/kg 
4 
mg/kg 
8 
mg/kg 
16 
mg/kg 
32 
mg/kg 
        
Body weight 
(g) 
343 ± 
7 
332 ± 
9 
351 
±14 
318 ± 
56 
345 ± 
12 
329 ± 
41 
341 ± 
14 
        
Lung 1.47 ± 
0.08 
1.54 ± 
0.20 
1.51 ± 
0.07 
1.50 ± 
0.16 
(3) 
1.53 ± 
0.10 
1.41 ± 
0.18 
1.52 ± 
0.17 
Heart 1.011 
± 0.04 
0.987 
± 0.08 
1.037 
± 0.08 
0.992 
± 0.07 
1.012 
± 0.08 
1.052 
± 0.04 
1.019 
± 0.06 
Liver 12.36 
± 0.27 
11.67 
±0.72 
12.40 
± 0.70 
11.03 
± 1.99 
12.80 
± 1.12 
11.18 
± 2.24 
11.92 
± 0.42  
Kidney 
(L+R) 
2.61 
±0.06 
2.46 ± 
0.25 
2.61 ± 
0.12 
2.38 ± 
0.42 
2.38 ± 
0.32 
2.45 ± 
0.52 
2.78 ± 
0.39 
Spleen 0.582 
± 0.03 
0.521 
±0.04 
0.582 
± 0.03 
0.436 
± 0.17 
0.595 
± 0.03 
0.540 
± 0.05 
0.599 
± 0.11 
Thymus 0.483 
± 0.07 
0.407 
± 0.04 
0.486 
± 0.04 
0.466 
± 0.06 
0.485 
± 0.03 
0.433 
± 0.13 
0.493 
± 0.06 
Mesenteric 
Lymph 
Node 
0.189 
± 0.04 
0.173 
± 0.01 
0.200 
± 0.01 
0.169 
± 0.01 
0.161 
± 0.02 
0.159 
± 0.02 
0.204 
± 
0.001 
Testes 
(L+R) 
2.97 ± 
0.09 
2.86 ± 
0.06 
3.10 ± 
0.21 
2.77 ± 
0.41 
2.89 ± 
0.24 
2.91 ± 
0.37 
2.98 
±0.07 
Brain 2.14 ± 
0.02 
2.09 ± 
0.04 
2.15 ± 
0.02 
2.08 ± 
0.09 
2.10 ± 
0.03 
2.08 ± 
0.11 
2.18 ± 
0.07 
Adrenals 0.041 
± 
0.004 
0.037 
± 
0.003 
0.042 
± 
0.002 
0.042 
± 
0.002 
0.040 
± 
0.007 
0.040 
± 
0.005 
0.040 
± 
0.003 
        
 
Table A. 5 Body and organ weights in male rats after 5 days consecutive oral administrations of CuO. 
At day 26 (21 days after the last administration). 
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Table A. 6 Bone marrow cellularity in male rats after 5 days consecutive oral administration of CuO. 
 
CuO         Pilot 
Study  
 Extra 
Study 
Dose  0 
mg/kg 
1 
mg/kg 
2 
mg/kg 
4 
mg/kg 
8 
mg/kg 
16 
mg/kg 
32 
mg/kg 
 64 
mg/kg 
 512 
mg/kga 
Day 6            
WBC 
x109/L 
8.56 ± 
2.67 
9.45 ± 
4.80 
4.79 ± 
2.99 
12.78 
± 
11.86 
11.35 
± 8.16 
8.19 
±2.45 
7.94 ± 
5.50 
 13.72 
± 
13.26 
(2) 
 
 10.45 
± 4.97 
Day 26            
WBC 
x109/L 
12.91 
± 5.51 
13.18 
± 6.91 
(3) 
12.20 
± 6.53 
11.19 
± 7.56 
(3) 
6.11 ± 
3.01 
12.10 
± 2.44 
(3) 
12.36 
± 2.01 
 NP  NP 
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Table A. 7 Haematology in male rats after 5 days consecutive oral administration of CuO - At day 6 (24 hours after the last 
administration). 
 
CuO         Pilot 
Study  
 Extra 
Study 
Dose  0 
mg/kg 
1 
mg/kg 
2 
mg/kg 
4 
mg/kg 
8 
mg/kg 
16 
mg/kg 
32 
mg/kg 
 64 
mg/kg 
 512 
mg/kga 
            
WBC 
x109/L 
5.07 ± 
0.53 
4.46 ± 
0.52 
5.27 ± 
0.7 
3.92 ± 
0.40*b 
4.40 ± 
0.41 
4.39 ± 
0.51 
3.98 ± 
0.24* 
 2.89 ± 
0.41**  
 9.53 ± 
1.47 
RBC 
x1012/L 
8.03 ± 
0.29 
7.96 ± 
0.15 
8.00 ± 
0.12 
8.12 ± 
0.10 
7.84 ± 
0.27 
7.81 ± 
0.12 
7.68 ± 
0.21 
 7.50 ± 
0.12*  
 8.33 ± 
0.92 
HgB 
Mmol/L 
8.60 ± 
0.36 
8.38 ± 
0.40 
8.60 ± 
0.16 
8.65 ± 
0.13 
8.43 ± 
0.26 
8.33 ± 
0.15 
8.05 ± 
0.21 
 8.07 ± 
0.19*  
 9.25 ± 
0.85 
Hct 
L/L 
0.415 
± 0.02 
0.403 
± 0.02 
0.410 
± 0.01 
0.420 
± 0.02 
0.402 
± 0.02 
0.403 
± 0.01 
0.400 
± 0.00 
 0.380 
± 
0.00* 
 0.218 
± 0.02 
MCV 
fl 
52 ± 
0.7 
50 ± 
1.7 
51 ± 
0.5 
51 ± 
0.6 
52 ± 
0.9 
52 ± 
0.4 
52 ± 
1.3 
 51 ± 
0.1  
 52 ± 
1.6 
MCH 
fmol 
1.07 ± 
0.01 
1.05 ± 
0.03 
1.08 ± 
0.02 
1.07 ± 
0.01 
1.07 ± 
0.01 
1.07 ± 
0.01 
1.05 ± 
0.00 
 1.07 ± 
0.01  
 1.12 ± 
0.02 
MCHC 
Mmol/L 
20.62 
± 0.22 
20.79 
± 0.20 
20.97 
± 0.25 
20.68 
± 0.24 
20.76 
± 0.31 
20.60 
± 0.17 
20.46 
± 0.48 
 20.77 
± 0.17  
 21.24 
± 0.33 
RDW 
% 
11.41 
± 0.19 
11.69 
± 0.59 
11.59 
± 0.19 
11.44 
± 0.18 
11.36 
± 0.19 
11.44 
± 0.18 
11.58 
± 0.11 
 11.60 
± 0.14  
 11.96 
± 0.21 
HDW 
Mmol/L 
1.45 ± 
0.06 
1.50 ± 
0.04 
1.51 ± 
0.01 
1.47 ± 
0.02 
1.43 ± 
0.04 
1.48 ± 
0.07 
1.43 ± 
0.10 
 1.43 ± 
0.05  
 1.6+7 
± 0.08 
PLT 
x109/L 
739 ± 
36 
577 ± 
204 
730 ± 
32 
728 ± 
18 
739 ± 
9 
692 ± 
146 
766 ± 
41 
 739 ± 
45  
 1196 ± 
236 
MPV 
fl 
6.70 ± 
0.23 
7.56 ± 
0.97 
6.90 ± 
0.25 
6.46 ± 
0.29 
6.90 ± 
0.43 
7.15 ± 
0.95 
6.45 ± 
0.42 
 6.82 ± 
0.26  
 7.56 ± 
0.70 
Neutrophils 
% 
9.9 ± 
0.6 
13.0 ± 
3.0 
11.1 ± 
1.7 
8.8 ± 
1.1 
11.7 ± 
0.8 
13.0 ± 
2.1 
11.2 ± 
1.1 
 15.0 ± 
2.1 
 27.5 ± 
13.6 
Lymphocytes 
% 
86.5 ± 
0.7 
80.8 
±4.6 
84.7 ± 
2.4 
85.5 ± 
2.0 
83.0 ± 
1.0 
81.4 ± 
2.8 
83.0 ± 
0.8* 
 81.4 ± 
2.6  
 67.2 ± 
15.4 
Monocytes 
% 
1.54 ± 
0.38 
1.80 ± 
0.54 
2.01 ± 
0.14 
1.66 ± 
0.21  
1.37 ± 
0.13 
1.71 ± 
0.20 
1.78 ± 
0.32 
 1.52 ± 
0.26  
 2.56 ± 
1.11 
Eosinophils 
% 
1.61 ± 
0.70 
3.99 ± 
1.51 
1.66 
0.69 
3.65 ± 
1.96 
3.76 ± 
0.32 
3.56 ± 
1.62 
3.68 ± 
0.18** 
 1.80 ± 
0.80  
 0.64 ± 
0.38 
LUC 
% 
0.30 ± 
0.12 
0.33 ± 
0.15 
0.46 ± 
0.08 
0.41 ± 
0.11 
0.23 ± 
0.05 
0.25 ± 
0.07 
0.35 ± 
0.28 
 0.18 ± 
0.02  
 2.01 ± 
1.38 
Basophils 
% 
0.05 ± 
0.04 
006  ± 
0.06 
0.05 ± 
0.10 
0.03 ± 
0.05 
0.09 ± 
0.04 
0.06 ± 
0.05 
0.05 ± 
0.00 
 0.10 ± 
0.09  
 0.08 ± 
0.03 
Reticulocytes 
% 
2.70 ± 
0.41 
2.69 ± 
0.44 
2.85 ± 
0.11 
2.49 ± 
0.34 
2.47 ± 
0.25 
2.98 ± 
0.38 
2.57 ± 
0.5 
 2.07 ± 
0.30  
 1.66 ± 
1.04 
Neutrophils 
x109/L 
0.50 ± 
0.08 
0.58 ± 
0.15 
0.59 ± 
0.16 
0.35 ± 
0.07 
0.51 ± 
0.07 
0.58 ± 
0.16 
0.44 ± 
0.01 
 0.44 ± 
0.13  
 2.49 ± 
1.09 
Lymphocytes 
x109/L 
4.39 ± 
0.44 
3.62 ± 
0.53 
4.45 ± 
0.48 
3.36 ± 
0.38 
3.64 ± 
0.33 
3.56 ± 
0.31 
3.30 ± 
0.23* 
 2.35 ± 
0.26** 
 6.56 ± 
2.54 
Monocytes 
x109/L 
0.08 ± 
0.02 
0.08 ± 
0.02 
0.11 ± 
0.02 
0.07 ± 
0.01 
0.06 ± 
0.01 
0.08 ± 
0.02 
0.07 ± 
0.01 
 0.04 ± 
0.00  
 0.23 ± 
0.09 
Eosinophils 
x109/L 
0.08 ± 
0.04 
0.17 ± 
0.05 
0.09 ± 
0.05  
0.14 ± 
0.07 
0.16 ± 
0.00 
0.16 ± 
0.07 
0.15 ± 
0.02 
 0.05 ± 
0.03 
 0.06 ± 
0.03 
LUC 
x109/L 
0.01 ± 
0.01 
0.01 ± 
0.01 
0.02 ± 
0.00 
0.02 ± 
0.01 
0.01 ± 
0.00 
0.01 ± 
0.01 
0.02 ± 
0.01 
 0.00 ± 
0.00  
 0.01 ± 
0.01 
Basophils 
x109/L 
0.00 ± 
0.00 
0.00 ± 
0.00 
0.00 ± 
0.00 
0.00 ± 
0.00 
0.00 ± 
0.00 
0.00 ± 
0.00 
0.00 ± 
0.00 
 0.00 ± 
0.00  
 0.18 ± 
0.10 
Reticulocytes 
x1012/L 
0.22 ± 
0.03 
0.21 ± 
0.03 
0.23 ± 
0.01 
0.20 ± 
0.03 
0.19 ± 
0.01 
0.23 ± 
0.03  
0.20 ± 
0.02 
 0.16 ± 
0.02  
 0.13 ± 
0.07 
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Table A. 8 Haematology in male rats after 5 days consecutive oral administration of CuO - At day 26 (21 days after the last 
administration). 
 
 
CuO         
Dose  0 
mg/kg 
 1 
mg/kg 
2 
mg/kg 
4 
mg/kg 
8 
mg/kg 
16 
mg/kg 
32 
mg/kg 
         
WBC 
x109/L 
5.40 ± 
0.99 
 5.95 ± 
1.18 
5.15 ± 
0.31 
4.87 ± 
0.80 
6.44 ± 
0.96 
5.60 ± 
1.13 
5.33 ± 
0.99 
RBC 
x1012/L 
8.54 ± 
0.25 
 8.55 ± 
0.06  
8.59 ± 
0.16 
8.66 ± 
0.27 
8.69 ± 
0.15 
8.77 ± 
0.31 
8.28 ± 
0.96 
HgB 
Mmol/L 
8.73 ± 
0.22 
 8.57 ± 
0.06 
8.55 ± 
0.29 
8.73 ± 
0.31 
8.85 ± 
0.25 
8.87 ± 
0.31 
8.44 ± 
0.83 
Hct 
L/L 
0.410 
± 0.01  
 0.413 
± 0.01 
0.405 
± 0.01 
0.413 
± 0.01 
0.425 
± 0.01 
0.427 
± 0.01 
0.398 
± 0.04 
MCV 
fl 
49 ± 
0.5 
 48 ± 
0.4 
47 ± 
0.3 
47 ± 
0.6 
49 ± 
0.3 
48 ± 
0.1 
48 ± 
0.8 
MCH 
fmol 
1.02 ± 
0.02 
 1.01 ± 
0.02 
1.00 ± 
0.01 
1.01 ± 
0.01 
1.02 ± 
0.01 
1.01 ± 
0.01 
1.02 ± 
0.02 
MCHC 
Mmol/L 
20.95 
± 0.14 
 20.92 
± 0.14 
21.00 
± 0.28 
21.26 
± 0.27 
20.94 
± 0.14 
21.07 
± 0.07 
21.21 
± 0.19 
RDW 
% 
11.49 
± 0.15 
 11.55 
± 0.09 
11.59 
± 0.14 
11.55 
± 0.22 
11.48 
± 0.12 
11.57 
± 0.15 
11.59 
± 0.19 
HDW 
Mmol/L 
1.71 ± 
0.03 
 1.74 ± 
0.01 
1.73 ± 
0.03 
1.80 ± 
0.05 
1.69 ± 
0.03 
1.75 ± 
0.03 
1.69 ± 
0.04 
PLT 
x109/L 
707 ± 
20 
 714 ± 
28 
693 ± 
26 
706 ± 
23 
678 ± 
60 
681 ± 
19 
749 ± 
69 
MPV 
fl 
7.14 ± 
0.29 
 6.98 ± 
0.24 
6.93 ± 
0.19 
7.15 ± 
0.44 
7.11 ± 
0.28 
7.23 ± 
0.51 
6.83 ± 
0.17 
Neutrophils 
% 
11.4 ± 
1.3 
 12.0 ± 
0.2 
10.8 ± 
2.0 
10.1 ± 
1.3 
12.0 ± 
2.1 
11.6 ± 
2.9 
10.8 ± 
2.4 
Lymphocytes 
% 
84.1 ± 
1.8 
 84.0 ± 
1.1 
85.0 ± 
2.6 
86.6 ± 
2.5 
84.0 ± 
2.4 
85.0 ± 
3.5 
83.5 ± 
4.2 
Monocytes 
% 
1.41 ± 
0.06 
 2.00 ± 
0.43 
1.88 ± 
0.48 
1.60 ± 
0.40 
1.78 ± 
0.46 
1.47 ± 
0.38 
1.85 ± 
0.48 
Eosinophils 
% 
2.68 ± 
2.08 
 1.43 ± 
0.68 
1.66 ± 
0.21 
1.35 ± 
0.74 
1.75 ± 
0.26 
1.33 ± 
0.25 
3.25 ± 
2.51 
LUC 
% 
0.39 ± 
0.22 
 0.45 ± 
0.13 
0.58 ± 
0.21 
0.38 ± 
0.16 
0.45 ± 
0.19 
0.55 ± 
0.26 
0.42 ± 
0.31 
Basophils 
% 
0.06 ± 
0.03 
 0.07 ± 
0.03 
0.03 ± 
0.03 
0.08 ± 
0.03 
0.04 ± 
0.05 
0.07 ± 
0.06 
0.12 ± 
0.04 
Reticulocytes 
% 
2.15 ± 
0.16 
 2.22 ± 
0.18 
2.12 ± 
0.06 
2.17 ± 
0.27 
2.00 ± 
0.12 
2.05 ± 
0.20 
2.24 ± 
0.43 
Neutrophils 
x109/L 
0.62 ± 
0.17 
 0.72 ± 
0.14 
0.56 ± 
0.12 
0.48 ± 
0.07 
0.76 ± 
0.04 
0.67 ± 
0.30 
0.59 ± 
0.24 
Lymphocytes 
x109/L 
4.54 ± 
0.86 
 5.01 ± 
1.06 
4.38 ± 
0.21 
4.22 ± 
0.75 
5.43 ± 
0.97 
4.73 ± 
0.76 
4.43 ± 
0.62 
Monocytes 
x109/L 
0.08 ± 
0.01 
 0.12 ± 
0.01 
0.10 ± 
0.03 
0.08 ± 
0.02 
0.11 ± 
0.01 
0.08 ± 
0.03 
0.09 ± 
0.00 
Eosinophils 
x109/L 
0.14 ± 
0.08 
 0.08 ± 
0.02 
0.08 ± 
0.02 
0.07 ± 
0.03 
0.12 ± 
0.03 
0.08 ± 
0.03 
0.19 ± 
0.17 
LUC 
x109/L 
0.02 ± 
0.02 
 0.03 ± 
0.01 
0.03 ± 
0.02 
0.02 ± 
0.01 
0.03 ± 
0.01 
0.03 ± 
0.02 
0.02 ± 
0.01 
Basophils 
x109/L 
0.00 ± 
0.00 
 0.00 ± 
0.00 
0.00 ± 
0.00 
0.00 ± 
0.00 
0.00 ± 
0.00 
0.00 ± 
0.00 
0.00 ± 
0.00 
Reticulocytes 
x1012/L 
0.18 ± 
0.01 
 0.19 ± 
0.01 
0.18 ± 
0.00 
0.19 ± 
0.02 
0.17 ± 
0.01 
0.18 ± 
0.02 
0.18 ± 
0.01 
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The results of the clinical chemistry are presented in Table A.9. At day 6 alterations in the level 
of alkaline phosphatase and aspartate aminotransferase enzymes indicated the presence of liver 
toxicity. At the highest dose of 64 mg/kg lactate dehydrogenase levels were also increased 
indicating cell and organ damage. Most of the alterations were no longer present at day 21 after 
treatment.  Animals treated with 512 mg/kg showed similar alterations in clinical chemistry 
(low level of alkaline phosphatase, high level of aspartate aminotransferase, and high level of 
lactate dehydrogenase) thus supporting the data of the dose-response study. 
 
Table A. 9 Clinical chemistry in male rats after 5 days consecutive oral administration of CuO - at day 26 (21 days after the 
last administration. 
 
CuO        
Dose  0 
mg/kg 
1 
mg/kg 
2 
mg/kg 
4 
mg/kg 
8 
mg/kg 
16 
mg/kg 
32 
mg/kg 
        
TP 
g/L 
49 ± 1 49 ± 1 49 ± 2 50 ± 1 
(3) 
<DL(1) 
51 ± 1 50 ± 1 52 ± 1 
ALB g/L 13.6 ± 
0.2 
13.5 ± 
0.6 
13.2 ± 
0.3 
13.6 ± 
0.3 (3) 
<DL(1) 
14.1 ± 
0.3 
13.8 ± 
0.3 
13.8 ± 
0.3 
ALP 
IU/L 
276 ± 
19 
290 ± 
21 
232 ± 
19* 
209 ± 
62 
274 ± 
30 
241 ± 
29 
236 ± 
44 
ALT 
IU/L 
49 ± 
4.9 
52 ± 
4.0 
46 ± 
4.1 
43 ± 5.4 50 ± 
5.9 
51 ± 
2.1 
46 ± 
2.0 
AST 
IU/L 
64 ± 
3.7 
70 ± 
6.7 
62 ± 
1.4 
63 ± 4.1 66 ± 
3.7 
65 ± 
4.4 
68 ± 
6.0 
GGT 
U/L 
0.44 ± 
0.2 (2) 
<DL(2) 
0.51 ± 
0.3 (3) 
<DL(1) 
0.15 ± 
0.1 
0.27 ± 
0.1 
0.73 ± 
0.3 (2) 
<DL(2) 
0.26 ± 
0.1 (3) 
<DL(1) 
0.54 ± 
0.1 (2) 
<DL(2) 
LDH 
IU/L 
635 ± 
129 
634 ± 
316 
585 ± 
223 
694 ± 
156 
547 ± 
242 
573 ± 
205 
822 ± 
131 
CHOL 
mmol/L 
1.26 ± 
0.06 
1.26 ± 
0..02 
1.26 ± 
0.09 
1.26 ± 
0.10 
1.24 ± 
0.05 
1.30 ± 
0.10 
1.40 ± 
0.20 
TG 
mmol/L 
1.21 ± 
0.15 
1.17 ± 
0.20 
1.27 ± 
0.30 
1.22 ± 
0.18 (3) 
<DL()1) 
1.49 ± 
0.20 
1.08 ± 
0.22 
1.41 ± 
0.26 
CRE 
µmol/L 
17.5 ± 
1.1 
18.5 ± 
2.6 
19.2 ± 
1.2 
20.9 ± 
1.8 (3) 
<DL(1) 
20.4 ± 
3.4 
19.9 ± 
2.3 
22.9 ± 
5.4 
GLU 
mmol/L 
10.8 ± 
1.2 
10.2 ± 
0.8 
10.2 ± 
0.3 
10.6 ± 
0.7 
10.4 ± 
0.6 
10.1 ± 
1.1 
10.9 ± 
0.3 
K 
mmol/L 
4.8 ± 
0.1 
4.8 ± 
0.2 
5.0 ± 
0.1 
4.8 ± 
0.2 
4.9 ± 
0.1 
4.9 ± 
0.3 
4.8 ± 
0.3 
Ca 
mmol/L 
2.58 ± 
0.06 
2.49 ± 
0.05 
2.53 ± 
0.05 
2.70 ± 
0.29 
2.52 ± 
0.02 
2.55 ± 
0.06 
2.54 ± 
0.06 
Cl 
mmol/L 
98 ± 
0.7 
100 ± 
1.2 
99 ± 
0.5 
98 ± 0.8 
(3) 
98 ± 
1.3 
98 ± 
0.8 
99 ± 
1.0 
Fe 
µmol/L 
36.3 ± 
1.9 
33.4 ± 
2.1 
35.4 ± 
1.4 
33.8 ± 
5.7 
35.3 ±  
2.0 
36.7 ± 
1.4 
40.1 ± 
4.2 
Na 
mmol/L 
142 ± 
0.7 
141 ± 
1.0 
141 ± 
0.6 
140 ± 
0.3 (3) 
141 ± 
0.4 
141 ± 
1.3 
142 ± 
1.5 
Urea 
mmol/l 
6.2 ± 
0.2 
6.1 ± 
0.3 
5.8 ± 
0.3 
6.8 ± 
1.7 
7.1 ± 
0.3 
6.1 ± 
0.4 
6.6 ± 
1.6 
Uric 
Acid 
43 ± 
10.4 
39 ± 
8.2 
43 ± 
5.3 
49 ± 
19.8 
41 ± 
4.5 
47 ± 
10.0 
45 ± 
7.2 
TBAX 
µmol/L 
43 ± 5 26 ± 
17 
33 ± 
13 
34 ± 17 50 ± 
13 
45 ± 
18 
31 ± 
12 
TBIL 
µmol/L 
7.1 ± 
1.0 
8.4 ± 
1.0 
7.8 ± 
0.8 
9.7 ± 
3.6 
7.5 ± 
0.7 
8.3 ± 
1.0 
7.7 ± 
0.9 
        
ROM 
IU/L 
265 ± 
28 
258 ± 
7 
255 ± 
12 
268 ± 
34 
266 ± 
16 
260 ± 
14 
288 ± 
35 
SHP 
µmol/L 
260 ± 
17 
272 ± 
11 
233 ± 
11 
216 ± 
54 
276 ± 
13 
240 ± 
9 
244 ± 
17 
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Histopathology - There were no test item-related microscopic observations in the initial dose-
response study up to a dose of 64 mg/kg (data not shown). All of the recorded microscopic 
findings were within the range of background pathology encountered in rats of this age and 
strain. There was no test item-related alteration in the prevalence, severity, or histologic 
character of those incidental tissue alterations in the initial dose-response study with doses up 
to 64 mg/kg. For animals treated in the additional study with a dose of 512 mg/kg and evaluated 
at day, 6 alterations were observed in stomach, liver, and bone marrow.  
• Bone marrow: Increased myeloid elements/decreased erythroid elements in the bone 
marrow of 1/3 rats (slight).  
• Stomach: An increased incidence and severity of submucosal glandular inflammation 
with eosinophilic granulocytes in 4/4 rats treated with 512 mg/kg CuO (1 slight, 3 
moderate) compared to 2/4 control rats (minimal).  
• Liver: Kupffer cell hypertrophy/hyperplasia in 2/4 rats (slight), inflammation (mixed 
inflammatory cells) in 2/4 rats (1 moderate, 1 marked), hepatocellular hypertrophy in 
3/4 rats (2 minimal, 1 moderate), hepatocellular necrosis in 3/4 rats (1 slight, 1 
moderate, 1 marked) and single cell necrosis (above the background level of minimal) 
in 2/4 rats (1 moderate, 1 marked).  
The histopathological observations in animals treated with 512 mg/kg confirm the effects seen 
in the clinical chemistry parameters. These clinical chemistry effects were already observed at 
doses for which no histopathological alterations were observed (up to 64 mg/kg CuO). 
Cu content of tissues - Cu content of tissues after 5 consecutive days of CuO oral administration 
is presented in Table A.10.  For the liver and mesenteric lymph node (MLN) also at the lower 
doses investigates (32 and 64 mg/kg) an increase in Cu content was noted. For the highest dose 
investigated (512 mg/kg) no statistical evaluation could be performed as contemporary controls 
were lacking. However, besides the liver and MLN also in the kidney, a clear increase was 
present when compared to vehicle-treated animals in the earlier experiment. For Thymus and 
spleen, the data indicate a trend for an increase at 512 mg/kg. At day 26 the increased levels of 
Cu in liver and kidney were returned to levels in the control animals range. 
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Table A. 10 Cu in organs of male rats after 5 days consecutive oral administration of CuO. 
 
Cytokine protein – Figure A.13 below shows the cytokine concentrations detected in each of 
the tissues examined following CuO treatment.  Analysis of variance of the data indicated that 
there was no significant increase or decrease in the amount of each cytokine at the doses chosen 
when compared with the control.  There was no IL-13 detected in any of the tissues examined.  
Only IL-1α and IL-1β were detected in all of the tissues; there was no evidence of an effect of 
dose on cytokine production.  IL-6 was detected only in liver tissue, and both IL-12 and TNF-
α were detected in stomach, colon and liver. There was no significant effect of oral CuO 
treatment at either dose investigated compared with the control treated animals. 
 
Day 6 Organ        
Treatment 
dose 
Liver Lung Kidney Spleen MLN Thymus Testis Brain 
cortex 
         
0 mg/kg 
control 
13 ± 
0.4a 
6 ± 1 41 ± 6 6 ± 0.4 5 ± 1 4 ± 0.3 11 ± 
0.3 
9 ± 0.1 
32 mg/kg 42 ± 
15.6* 
6 ± 1 62 ± 
14 
6 ± 0.3 8 ± 2 5 ± 1 (3) 11 ± 
0.1 
9 ± 0.5 
64 mg/kg 75 ± 
4.5 (2)* 
5 (1) 64 (1) 6 ± 1 
(2) 
10 ± 0.3 
(2)*** 
8 ± 4 (2) 11 ± 
0.3 
(2) 
Nd  
512 
mg/kg 
914 ± 
541 
70 ± 
69 
76 ± 
42 
10 ± 5 26 ± 11 10 ± 7 12 ± 
1 
10 ± 1 
         
Day 26         
0 mg/kg 
control 
14 ± 0.3 7 ± 
0.2 
62 ± 9 6 ± 0.6 4 ± 2 5 ± 1 12 ± 
1 
10 ± 3 
32 mg/kg 12 ± 1.5 6 ± 
1.3 
52 ± 4 
(3)  
5 ± 0.9 5 ± 2 5 ± 2 11 ± 
1 
9 ± 0.4 
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Figure A. 13 cytokine protein concentrations (µg/mg protein) present in selected tissues from rats dosed orally with 16 and 
32mg/kg of CuO and sacrificed at day 6 after oral treatment for 5 consecutive days (days 1-5). Data represent the mean±SEM 
of each cytokine detected (µg/mg protein) and represents data from four separate animals.   
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GSH and reduced GSH in the liver - After CuO treatment, there was a significant increase in 
the total GSH in the livers of animals treated with 16 and 32mg/kg (p<0.01 and p<0.001 
respectively) compared with controls.  In contrast, in animals treated with 512mg/kg, there was 
a significant decrease (p<0.05) in the amount of total GSH.  In animals treated with 32 and 
512mg/kg CuO, there was a significant increase in the amount of reduced GSH (p<0.05 and 
p<0.01 respectively) compared with controls (Figure A.14). 
 
 
Figure A. 14 GSH concentration (total and reduced forms) (µg/mg protein) present in the liver of rats dosed orally with 16, 
32 and 512mg/kg of CuO and 64 and 128mg/kg of CuCO3. Animals were sacrificed at day 6 after oral treatment for 5 
consecutive days (days 1-5). Data represent the mean±SEM of GSH (µg/mg protein) and represents data from four separate 
animals.  (*p<0.05; **p<0.01; ***p<0.001 compared with the control). 
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Conclusions on oral CuO administration  
 
For some of the parameters the dose-response study with lower doses (up tp 32 and 64 mg/kg) 
some indications for liver toxicity was noted. The investigational high dose (512 mg/kg) study 
group that was later added confirmed the occurring liver toxicity, also confirmed by 
histopathology. Table 8 shows a further statistical evaluation of the outcomes of the oral CuO 
studies by using the benchmark dose (DMB) approach. This analysis shows that only for effects 
on the liver enzyme AST and the red blood cell parameters an effect could be demonstrated. 
The histopathology confirms the indication for liver toxicity by the effect on the AST enzyme, 
as it showed liver lesions after oral exposure to CuO at high doses.  
 
Results: CuCO3 - General toxicity 
 
For CuCO3 a dose range finding study was performed according to OECD 425 (Acute oral 
toxicity, Up and Down Procedure). The dose according to OECD 425 was administered once, 
and the animals were followed by signs of toxicity. Toxicity signs for evaluation were: pain, 
abnormal behaviour, isolation, diarrhoea, exudation, breathing, and severe weight loss and 
death. The dose of 128 mg/kg was found to be suitable for oral administration.  
Repeated (5 times) oral administration of a dose of 128 mg/kg CuCO3 induced severe toxic 
responses in the treated animals as indicated by the behaviour of the animals, frequent washing 
and piloerection. Based on these observations the animals scheduled for prolonged observation 
(autopsy after a recovery period at day 21 after treatment) were autopsied prematurely at days 
6 and 7, respectively 24 and 48 hours after the last (day 5) treatment.  Table A.11 shows the 
body and organ weights at day 6 and 7.  At day 6 a decrease in body weight was present for the 
group of animals that were treated with a dose of 128 mg/kg body weight. This was mainly 
observed for the “recovery” group, although there was no difference between the treatment or 
recovery durations imposed on animals in each group at this time point. Heart, liver, spleen 
and thymus showed a decrease in weight, whereas adrenal weights were increased, the latter 
probably indicating a stress response due to the toxicity of the CuCO3.  
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Table A. 11 Body and organ weight in male rats after 5 days consecutive oral administration of CuCO3 - At day 6 (24 hours 
after the last administration). 
 
Haematology and Clinical chemistry - An overview of haematological parameters after five-
day oral administration of CuCO3 nanoparticles is presented in Table A.12.  At day 6 an 
increase in WBC was present for doses of 32 mg/kg. The increase in WBC was due to an 
absolute (and also relative) increase in neutrophilic granulocytes. The decrease in a relative 
number of lymphocytes can be attributed to the increase in neutrophilic granulocytes. The 
absolute number of lymphocytes was not affected by the CuCO3 nanoparticles treatment. Data 
for day 26 are shown in Table A.13. At day 26 no alterations in haematological parameters 
were observed. 
CuCO3            
Dose  0 
mg/kg 
4 
mg/kg 
8 
mg/kg 
16 
mg/kg 
32 
mg/kg 
64 
mg/kg 
128 
mg/kg 
 128 
mg/kga 
  
            
Body 
weight (g) 
345 ± 
11 
385 
±24 
394 ± 
58 
367 ± 
15 
362 
±11 
344 ± 
29 
327 ± 
73 
 290 ± 
16** 
  
            
Lung 1.48 ± 
0.11 
1.56 ± 
0.15 
1.50 ± 
0.04 
1.50 ± 
0.08 
1.36 ± 
0.35 
1.51 ± 
0.53 
1.46 ± 
0.17 
 1.34 ± 
0.16 
  
Heart 1.210 
± 0.05 
1.279 
± 0.07 
1.300 
± 0.08 
1.244 
±0.09 
1.140 
± 0.06 
1.185 
± 0.16 
1.002 
± 
0.14* 
 0.928 ± 
0.02** 
  
Liver 13.40 
± 0.57 
15.68 
± 1.52 
15.14 
± 1.24 
14.79 
± 0.25 
14.42 
± 0.90 
14.15 
± 2.22 
10.79 
± 
1.22** 
 10.43 ± 
1.33** 
  
Kidney 
(L+R) 
2.23 ± 
0.15 
2.35 ± 
0.14 
2.38 ± 
0.05 
2.26 ± 
0.11 
2.21 ± 
0.25 
2.29 ± 
0.30 
2.00 ± 
0.75 
 2.14 ± 
0.45 
  
Spleen 0.992 
± 0.09 
1.040 
± 0.16 
1.032 
± 0.20 
0.955 
± 0.09 
1.020 
± 0.26 
1.059 
± 0.15 
0.508 
± 
0.08** 
 0.540 ± 
0.16** 
  
Thymus 0.706 
± 0.13 
0.789 
± 0.10 
0.826 
± 0.04 
0.745 
± 0.16 
0.798 
± 0.21 
0.717  
± 0.19 
0.221 
± 
0.06** 
 0.192 ± 
0.06** 
  
Mesenteric 
Lymph 
Node 
0.254 
± 0.06 
0.265 
± 0.05 
0.227 
± 0.03 
0.188 
± 0.03 
0.263 
± 0.03 
0.224 
± 0.08 
0.210 
± 0.04 
 0.222 ± 
0.06 
  
Testes 
(L+R) 
3.33 ± 
0.23 
3.42 ± 
0.37 
3.26 ± 
0.38 
2.66 ± 
0.17 
3.11 ± 
0.28 
3.29 ± 
0.37 
3.02 ± 
0.29  
 3.06 ± 
0.34 
  
Brain 1.92 ± 
0.03 
1.94 ± 
0.05 
1.88 ± 
0.02 
1.93 ± 
0.08 
1.88 ± 
0.11 
1.91 ± 
0.08 
1.86 ± 
0.07 
 1.84 ± 
0.11 
  
Adrenals 0.043 
± 
0.004 
0.051 
± 
0.009 
0.051 
± 
0.006 
0.051 
± 
0.006 
0.052 
± 
0.005 
0.051 
± 
0.004 
0.071 
± 
0.015* 
 0.063  
±  
0.008** 
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Table A. 12 Hematology in male rats after 5 days consecutive oral administration of CuCO3 - At day 6 (24 hours after the last 
administration). 
 
CuCO3 
 
         
Dose  0 
mg/kg 
4 
mg/kg 
8 
mg/kg 
16 
mg/kg 
32 
mg/kg 
64 
mg/kg 
128 
mg/kg 
 128 
mg/kga 
          
WBC 
x109/L 
8.29 ± 
1.56 
(3) 
13.10 ± 
1.75 
11.46 ± 
0.55 
10.78 ± 
1.72 
13.48 ± 
3.13 
16.37 
± 4.85* 
17.49 
± 7.8* 
 18.35 ± 
6.8 
RBC 
x1012/L 
7.32 ± 
0.26 
7.57 ± 
0.3 
7.27 ± 
0.4 
7.20 ± 
0.35 
7.32 ± 
0.36 
7.51 ± 
0.25 
9.36 ± 
1.5** 
 8.38 ± 
0.17 
HgB 
Mmol/L 
8.23 ± 
0.4 
8.48 ± 
0.56 
8.45 ± 
0.31 
8.30 ± 
0.35 
8.20 ± 
0.39 
8.68 ± 
0.22 
10.0 ± 
0.92** 
 9.43 ± 
0.21 
Hct 
L/L 
0.40 ± 
0.02 
0.41 ± 
0.03 
0.41 ± 
0.01 
0.40 ± 
0.02 
0.40 ± 
0.02 
0.42 ± 
0.01 
0.48 ± 
0.05** 
 0.45 ± 
0.01 
MCV 
fl 
54 ± 1 54 ± 1 57 ± 3 55 ± 1 54 ± 1 55 ± 1 52 ± 4  54 ± 2 
MCH 
fmol 
1.12 ± 
0.02 
1.12 ± 
0.04 
1.17 ± 
0.06 
1.15 ± 
0.03 
1.12 ± 
0.01 
1.16 ± 
0.04 
1.08 ± 
0.11 
 1.12 ± 
0.05 
MCHC 
Mmol/L 
20.6 ± 
0.11 
20.7 ± 
0.23 
20.3 ± 
0.36 
20.8 ± 
0.10 
20.6 ± 
0.11 
20.9 ± 
0.46 
20.8 ± 
0.86 
 20.8 ± 
0.29 
RDW 
% 
12.23 ± 
0.37 
12.75 ± 
0.44 
12.44 ± 
0.63 
12.30 ± 
0.55 
12.44 ± 
0.43 
12.10 ± 
0.88 
13.08 ± 
1.44 
 13.37 ± 
0.8 
HDW 
Mmol/L 
1.62 ± 
0.04 
1.64 ± 
0.06 
1.65 ± 
0.04 
1.68 ± 
0.06 
1.66 ± 
0.04 
1.67 ± 
0.12 
2.01 ± 
0.28 
 1.91 ± 
0.10 
PLT 
x109/L 
969 ± 
79 
956 ± 
114 
1160 ± 
172 
915 ± 
200 
1033 
±94 
971 ± 
241 
1171 ± 
102 
 1135 ± 
35 
MPV 
fl 
6.27 ± 
0.50 
6.58 ± 
0.68 
6.28 ± 
0.58 
6.46 ± 
0.25 
6.56 ± 
0.73 
7.16 ± 
1.73 
6.64 ± 
1.35 
 6.33 ± 
0.50 
Neutrophils 
% 
16.4 ± 
2.6 
15.8 ± 
1.5 
13.2 ± 
4.4 
16.0 ± 
3.2 
17.0 ± 
2.4 
16.8 ± 
3.7 
55.5 ± 
14.1** 
 49.5 ± 
7.4 
Lymphocytes 
% 
78.9 ± 
3.2 
79.1 ± 
1.8 
82.3 ± 
5.1 
79.5 ± 
3.3 
78.0 ± 
2.8 
77.3 ± 
4.2 
35.1 ± 
16** 
 39.4 ± 
9.4 
Monocytes 
% 
2.2 ± 
0.5 
2.7 ± 
0.5 
2.5 ± 
0.4 
2.2 ± 
0.3 
2.7 ± 
0.5 
3.8 ± 
0.3 
6.0 ± 
0.7** 
 7.2 ± 
0.5 
Eosinophils 
% 
2.0 ± 
0.8 
1.8 ± 
0.4 
1.5 ± 
0.6 
1.7 ± 
0.1 
1.6 ± 
0.6 
1.4 ± 
0.4 
0.7 ± 
0.1 
 0.8 ± 
0.4 
LUC 
% 
0.5 ± 
0.3 
0.5 ± 
0.1 
0.4 ± 
0.1 
0.5 ± 
0.1 
0.6 ± 
0.4 
0.6 ± 
0.1 
2.6 ± 
2.1 
 3.2 ± 
1.8 
Basophils 
% 
0.03 ± 
0.06 
0.13 ± 
0.05 
0.09 ± 
0.03 
0.11 ± 
0.03 
0.08 ± 
0.05 
0.10 ± 
0.09 
0.08 ± 
0.05 
 0.05 ± 
0.00 
Reticulocytes 
% 
3.29 ± 
0.16 
3.27 ± 
0.22 
4.05 ± 
0.25 
3.65 ± 
0.62 
3.30 ± 
0.61 
1.74 ± 
0.25 
0.85 ± 
0.11 
 1.07 ± 
0.12 
Neutrophils 
x109/L 
1.36 ± 
0.4 
2.06 ± 
0.3 
1.53 ± 
0.6 
1.70 ± 
0.2 
2.25 ± 
0.4 
2.69 ± 
0.7  
10.1 ± 
6.1** 
 9.3 ± 
4.4 
Lymphocytes 
x109/L 
6.52 ± 
1.1 
10.37 ± 
1.5 
9.42 ± 
0.4 
8.60 ± 
1.7 
10.54 ± 
2.6 
12.75 
± 4.1* 
5.59 ± 
1.9 
 6.95 ± 
2.3 
Monocytes 
x109/L 
0.19 ± 
0.08 
0.36 ± 
0.09 
0.28 ± 
0.05 
0.24 ± 
0.06 
0.38 ± 
0.14 
0.61 ± 
0.15 
1.08 ± 
0.56** 
 1.33 ± 
0.55 
Eosinophils 
x109/L 
0.17 ± 
0.05 
0.23 ± 
0.03 
0.18 ± 
0.08 
0.18 ± 
0.03 
0.22 ± 
0.09 
0.21 ± 
0.06 
0.12 ± 
0.04 
 0.15 ± 
0.10 
LUC 
x109/L 
0.05 ±  
0.04 
0.07 ± 
0.02 
0.06 ± 
0.01 
0.05 ± 
0.02 
0.09 ± 
0.07 
0.11 ± 
0.05 
0.57 ± 
0.56* 
 0.60 ± 
0.51 
Basophils 
x109/L 
0.00 ± 
0.00 
0.01 ± 
0.01 
0.01 ± 
0.01 
0.01 ± 
0.01 
0.01 ± 
0.01 
0.02 ± 
0.02 
0.01 ± 
0.01 
 0.01 ± 
0.01 
Reticulocytes 
x1012/L 
0.24 ± 
0.02 
0.25 ± 
0.02 
0.29 ± 
0.02* 
0.26 ± 
0.04 
0.24 ± 
0.04 
0.13 ± 
0.02** 
0.08 ± 
0.01*** 
 0.09 ± 
0.01 
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Table A. 13 Hematology in male rats after 5 days consecutive oral administration of CuCO3 - At day 26 (21 days after the last 
administration). 
 
 
CuCO3 
 
      
Dose  0 
mg/kg 
4 
mg/kg 
8 
mg/kg 
16 
mg/kg 
32 
mg/kg 
64 
mg/kg 
       
WBC 
x109/L 
10.50 
± 1.75 
13.33 
± 2.62 
10.76 
± 1.90 
12.31 
± 1.47 
11.93 
± 2.53 
9.67 ± 
1.38 
RBC 
x1012/L 
7.90 ± 
1.14 
7.94 ± 
0.21 
7.95 ± 
0.34 
7.85 
±0.26 
7.83 ± 
0.21 
7.84 ± 
0.15 
HgB 
Mmol/L 
8.40 ± 
0.33 
8.53 ± 
0.36 
8.55 ± 
0.41 
8.38 ± 
0.26 
8.28 ± 
0.15 
8.13 ± 
0.33 
Hct 
L/L 
0.42 ± 
0.02 
0.41 ± 
0.02 
0.41 ± 
0.02 
0.41 ± 
0.01 
0.41 ± 
0.01 
0.39 ± 
0.01 
MCV 
fl 
52 ±2 52 ±1 52 ±1 52 ±0 52 ±1 50 ± 2 
MCH 
fmol 
1.07 ± 
0.05 
1.07 ± 
0.03 
1.08 ± 
0.03 
1.06 ± 
0.01 
1.06 ± 
0.02 
1.04 ± 
0.04 
MCHC 
Mmol/L 
20.4 ± 
0.1 
20.7 ± 
0.3 
20.8 ± 
0.3 
20.6 ± 
0.2 
20.4 ± 
0.2 
20.7 ± 
0.2 
RDW 
% 
12.71 
± 0.40 
13.24 
± 0.41 
12.64 
± 0.39 
13.23 
±0.81 
13.76 
± 0.64 
13.61 
± 0.68 
HDW 
Mmol/L 
1.79 ± 
0.09 
1.95 ± 
0.13 
1.91 
±0.04 
1.90 
±0.09 
1.98 ± 
0.11 
1.94 
±0.06 
PLT 
x109/L 
915 ± 
69 
717 ± 
128 
932 ± 
143 
981 ± 
48 
919 ± 
74  
939 ± 
78 
MPV 
fl 
6.58 ± 
0.53 
6.93 ± 
0.73 
7.15 ± 
1.01 
6.71 ± 
0.24 
6.20 ± 
0.35 
6.67 ± 
0.25 
Neutrophils 
% 
17.5 ± 
5.2 
19.7 ± 
4.5 
13.4 ± 
2.2 
18.7 ± 
1.3 
20.2 ± 
7.0 
17.7 ± 
3.7 
Lymphocytes 
% 
79.0 ± 
5.1 
75.4 ± 
3.3 
82.6 ± 
3.5 
77.6 ± 
1.7 
75.2 ± 
6.3 
78.5 ± 
3.4 
Monocytes 
% 
2.03 ± 
0.41 
3.06 ± 
1.29 
2.40 ± 
1.31 
2.11 ± 
0.44 
2.69 ± 
0.86 
1.76 ± 
0.29 
Eosinophils 
% 
1.15 ± 
0.25 
1.40 ± 
0.18 
1.26 ± 
0.27 
1.38 ± 
0.29 
1.40 ± 
0.44 
1.60 ± 
0.56 
LUC 
% 
0.2 ± 
0.1 
0.3 ± 
0.2 
0.3 ± 
0.2 
0.2 ± 
0.0 
0.4 ± 
0.2 
0.3 ± 
0.2 
Basophils 
% 
0.11 ± 
0.03 
0.10 ± 
0.04 
0.06 ± 
0.05 
0.08 ± 
0.03 
0.10 ± 
0.04 
0.09 ± 
0.02 
Reticulocytes 
% 
3.07 ± 
0.28 
3.05 ± 
0.42 
2.68 ± 
0.35 
3.38 ± 
0.37 
3.28 ± 
0.40 
3.31 ± 
0.39 
Neutrophils 
x109/L 
1.86 ± 
0.75 
2.56 ± 
0.45 
1.47 ± 
0.48 
2.29 ± 
0.24 
2.29 ± 
0.42 
1.73 ± 
0.51 
Lymphocytes 
x109/L 
8.27 ± 
1.34 
10.10 
± 2.29 
8.84 ± 
1.20 
9.56 ± 
1.18 
9.08 ± 
2.62 
7.56 ± 
0.91 
Monocytes 
x109/L 
0.22 ± 
0.06 
0.43 ± 
0.22 
0.27 ± 
0.18 
0.26 ± 
0.09 
0.34 ± 
0.17 
0.17 ± 
0.05 
Eosinophils 
x109/L 
0.12 ± 
0.01 
0.19 ± 
0.05 
0.14 ± 
0.06 
0.17 ± 
0.04 
0.16 ± 
0.04 
0.15 ± 
0.05 
LUC 
x109/L 
0.03 ± 
0.01 
0.05 ± 
0.03 
0.04 ± 
0.02 
0.02 ± 
0.00 
0.06 ± 
0.04 
0.03 ± 
0.03 
Basophils 
x109/L 
0.01 ± 
0.01 
0.01 ± 
0.01 
0.01 ± 
0.01 
0.01 ± 
0.01 
0.01 ± 
0.01 
0.00 ± 
0.00 
Reticulocytes 
x1012/L 
0.24 ± 
0.02 
0.24 ± 
0.03 
0.21 ± 
0.03 
0.27 ± 
0.02 
0.26 ± 
0.03 
0.26 ± 
0.03 
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Bone marrow - There was no treatment-related effect in the cellularity of the bone marrow after 
treatment with CuCO3 nanoparticles (Table A.14). However, by microscopical evaluation of 
the bone marrow, there was a shift into myeloid cells of the bone marrow that was confirmed 
by histopathology.  
 
Table A. 14 Bone marrow cellularity in male rats after 5 days consecutive oral administration of CuCO3. 
 
Clinical chemistry - The results of the clinical chemistry are presented in Table A.15 and A.16. 
At day 6 alkaline phosphatase was decreased while aspartate aminotransferase, alanine 
aminotransferase, and lactate dehydrogenase were increased. These enzyme alterations in the 
blood indicate both liver and organ toxicity. In addition, free fatty acids, creatinine, iron and 
potassium levels in blood were increased. At day 26 only some incidental alterations were 
observed in clinical chemistry parameters, and most parameters were back to levels similar to 
control vehicle-treated animals. 
CuCO3          
Dose  0 
mg/
kg 
4 
mg/k
g 
8 
mg/k
g 
16 
mg/k
g 
32 
mg/k
g 
64 
mg/k
g 
128 
mg/k
g 
 128 
mg/kg
a 
Day 6          
WBC 
x109/L 
21.2
5 ± 
6.72 
22.90 
± 8.84 
22.88 
± 2.27 
18.80 
± 
11.21 
15.90 
± 3.80 
14.68 
± 3.37 
13.60 
± 2.72 
 18.09 
±2.09 
Day 26          
WBC 
x109/L 
16.7
1 ± 
4.09 
23.29 
± 6.18 
18.86 
± 4.63 
17.94 
± 8.94 
18.82 
± 6.32 
17.47 
± 4.09 
NP  NP 
          
Erythroid BM cells 
(%) 
45.8 
± 4.3  
     16 ± 
4.4 
(3)**
* 
 22.8 ± 
8.7*** 
Myeloid/ 
Lymphoid BM 
cells (%) 
54.2 
± 4.3 
     84 ± 
4.4 
(3)**
* 
 77.2 ± 
8.7*** 
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Table A. 15 Clinical chemistry in male rats after 5 days consecutive oral administration of CuCO3 - At day 6 (24 hours after 
the last administration). 
 
CuCO3          
Dose  0 
mg/kg 
4 
mg/kg 
8 
mg/kg 
16 
mg/kg 
32 
mg/kg 
64 
mg/kg 
128 
mg/kg 
 128 
mg/kga 
          
TP 
g/L 
55.4 ± 
0.6 
55.9 ± 
0.8 
56.5 ± 
1.2 
54.7 ± 
2.2 
53.5 ± 
1.4 
50.3 ± 
2.5* 
55.8 ± 
3.7 (3) 
 52.1 ± 
4.3 (3) 
ALB 
g/L 
15.7 ± 
0.6 
16.0 ± 
0.5 
15.9 ± 
0.7 
16.1 ± 
0.8 
15.0 ± 
0.7 
14.2 ± 
1.5 
15.9 ± 
1.8 (3) 
 14.5 ± 
0.9 (3) 
ALP 
IU/L 
222 ± 
35 
256 ± 
20 
208 ± 
16 
266 ± 
48  
238 ± 
19 
247 ± 
51 
80 ± 
21** 
 116 ± 
18** 
ALT 
IU/L 
54 ± 2 59 ± 4 57 ± 
13 
58 ± 
10 
60 ± 
14 
310 ± 
94** 
409 ± 
360 
 612 ± 
186** 
AST 
IU/L 
93 ± 9 96 ± 8 97 ± 
15 
101 ± 
10 
113 ± 
19 
438 ± 
110** 
1224 ± 
545* 
 1771 
± 
1122* 
GGT 
U/L 
0.36 ± 
0.2 (3) 
<DL(1) 
0.50 ± 
0.1 (2) 
<DL(2) 
0.35 ± 
0.1 (2) 
<DL(1) 
047 ± 
0.3 (2) 
<DL(2) 
0.55 
(1) 
<DL(2) 
0.32 ± 
0.2 (3) 
<DL(1) 
0.27 ± 
0.2 (3) 
<DL(1) 
 7.1 (1) 
LDH 
IU/L 
2229 ± 
468 
1796 ± 
455 
2556 ± 
656 
2229 ± 
710 
2754 ± 
462 
3139 ± 
1726 
9406 ± 
4903* 
 3667 ± 
1173 
FFA 
Mmol/L 
0.17 ± 
0.04 
0.20 ± 
0.1 
0.19 ± 
0.03 
0.19 ± 
0.04 
0.25 ± 
0.04  
0.42 ± 
0.2** 
0.65 ± 
0.1** 
 0.62 ± 
0.2** 
CHOL 
mmol/L 
1.21 ± 
0.1 
1.40 ± 
0.2 
1.32 ± 
0.1 
1.42 ± 
0.2 
1.23 ± 
0.2 
1.88 ± 
0.4* 
1.58 ± 
0.4 
 2.44 ± 
0.5** 
TG 
mmol/L 
1.70 ± 
0.44 
1.71 ± 
0.37 
2.45 ± 
0.47 
1.97 ± 
0.24 
1.84 ± 
0.29 
1.59 ± 
0.6 
1.23 ± 
0.5 
 1.06 ± 
0.28 
CRE 
µmol/L 
22.6 ± 
2.2 
21.7 ± 
3.5 
23.7 ± 
0.9 
24.2 ± 
2.4 
25.0 ± 
3.1 
23.0 ± 
3.2  
190 ± 
110 (3)** 
 56.2 ± 
49 
GLU 
mmol/L 
11.8 ± 
0.8 
11.0 ± 
0.5 
11.6 ± 
1.2 
11.6 ± 
1.1 
10.8 ± 
0.3 
10.2 ± 
1.3 
7.1 ± 
2.0** 
 9.6 = 
4.0 
K 
mmol/L 
4.81 ± 
0.2 
4.94 ± 
0.4 
4.90 ± 
0.1 
4.89 ± 
0.4 
5.00 ± 
0.2 
5.24 ± 
0.5  
6.10 ± 
0.6 
(3)* 
 5.59 ± 
0.2 
(3)* 
Ca 
mmol/L 
2.49 ± 
0.04 
2.60 ± 
0.04* 
2.57 ± 
0.03* 
2.59 ± 
0.06 
2.55 ± 
0.01* 
2.53 ± 
0.02 
2.56 ± 
0.18 
 2.53 ± 
0.15 
Cl 
mmol/L 
101 ± 
1.5 
100 ± 
0.4 
101 ± 
0.9 
100 ± 
2 
101 ± 
0.7 
104 ± 
0.8* 
99 ± 0.9 
(3) 
 102 ± 
1.5 (3) 
Fe 
µmol/L 
30.9 ± 
2 
36.3 ± 
4 
39.7 ± 
6* 
51.3 ± 
11* 
64.8 ± 
19* 
43.3 ± 
24 
66.5 ± 
23* 
 51.6 ± 
33 
Na 
mmol/L 
142 ± 
0.5 
141 ± 
0.5 
142 ± 
2.0 
143 ± 
3.3 
142 ± 
0.6 
143 ± 
1.8 
137 ± 
3.7 (3) 
 140 ± 
2.4 (3) 
Urea 
mmol/l 
6.06 ± 
1.0 
6.44 ± 
0.7 
5.78 ± 
1.2 
6.48 ± 
0.6 
6.24 ± 
0.7 
5.47 ± 
0.6 
25.8 ± 
14.5 
 13.3 ± 
5.3 
Uric 
Acid 
69 ± 
27 
53 ± 4 74 ± 
12 
50 ± 5 66 ± 7 55 ± 6 151 ± 
49* 
 119 ± 
58 
TBIL 
µmol/L 
5.96 ± 
0.19 
5.33 ± 
0.62 
5.55 ± 
0.66 
5.75 ± 
0.5 
6.38 ± 
0.75 
6.11 ± 
0.4 
13.73 ± 
9.66 
 12.92 
± 7.65 
ROM 
IU/L 
292 ± 
30 
280 ± 
22 
256 ± 
14 
261 ± 
8 
246 
±16 
332 ± 
35 
406 ± 
189 
 360 ± 
47 
SHP 
µmol/L 
323 ± 
41 
373 ± 
27 
335 ± 
16 
354 ± 
20 
328 ± 
13 
277 ± 
36  
197 ± 
160 
 148 ± 
112* 
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Table A. 16 Clinical chemistry in male rats after 5 days consecutive oral administration of CuCO3 - at day 26 (21 days after 
the last administration). 
 
Histopathology - Test item-related microscopic findings were observed in a number of organs 
examined after treatment with 64 or 128 mg/kg CuO3. These findings comprised: 
Starting at 64 mg/kg CuCO3:      
CuCO3       
Dose  0 
mg/kg 
4 
mg/kg 
8 
mg/kg 
16 
mg/kg 
32 
mg/kg 
64 
mg/kg 
       
TP 
g/L 
58.6 ± 
2.4 
56.9 ± 
2.7 
56.4 ± 
3.0 
59.4 ± 
1.7 
57.5 ± 
1.9 
57.1 ± 
1.6 
ALB g/L 16.3 ± 
0.7 
15.5 ± 
1.0 
15.3 ± 
1.1 
16.8 ± 
0.2 
16.6 ± 
0.5 
16.0 ± 
1.3 
ALP 
IU/L 
205 ± 
18 
188 ± 
24 
178 ± 
31 
229 ± 
40 
197 ± 
28 
256 ± 
39 
ALT 
IU/L 
63.7 ± 
4.7 
70.4 ± 
9.6 
48.5 ± 
3.8** 
69.3 ± 
13.1 
66.0 ± 
8.3 
87.2 ± 
32.3 
AST 
IU/L 
120 ± 
7 
110 ± 
9 
92 ± 
6** 
121 ± 
10  
112 ± 
5 
153 ± 
55 
GGT 
U/L 
0.71 
(1) 
<DL(3) 
0.49 ± 
0.0 (2) 
<DL(1) 
1.11 
(1) 
<DL(3) 
0.44 
(1) 
<DL(3) 
0.67 ± 
0.3 (2) 
<DL(2) 
0.69 ± 
0.2 (3) 
<DL(1) 
LDH 
IU/L 
3271 ± 
548 
2108 
± 333* 
1878 
± 455* 
2254 ± 
688 
2217 ± 
657 
2488 ± 
636 
CHOL 
mmol/L 
1.32 ± 
0.2 
1.39 ± 
0.1 
1.47 ± 
0.1 
1.40 ± 
0.1 
1.14 ± 
0.1 
1.28 ± 
0.1 
TG 
mmol/L 
2.20 ± 
0.89 
2.58 ± 
0.80 
2.27 ± 
0.65 
2.84 ± 
1.03 
2.19 ± 
0.91 
1.80 ± 
0.28 
CRE 
µmol/L 
27.2 ± 
2.1 
28.4 ± 
1.8 
28.0 ± 
2.3 
31.6 ± 
2.7 
29.4 ± 
2.3 
31.2 ± 
1.5* 
GLU 
mmol/L 
11.3 ± 
1.8 
10.8 ± 
1.3 
13.8 ± 
2.5 
11.4 ± 
0.8 
11.1 ± 
0.7 
12.3 ± 
1.1 
K 
mmol/L 
4.84 ± 
0.3 
5.08 ± 
0.3 
4.80 ± 
0.3 
4.94 ± 
0.4 
4.86 ± 
0.3 
4.74 ± 
0.1 
Ca 
mmol/L 
2.50 ± 
0.03 
2.55 ± 
0.05 
2.49 ± 
0.07 
2.50 ± 
0.04 
2.53 ± 
0.05 
2.47 ± 
0.06 
Cl 
mmol/L 
102 ± 
1.3 
102 ± 
1.1 
102 ± 
1.4 
101 ± 
1.5 
102 ± 
1.7 
102 ± 
1.0 
Fe 
µmol/L 
30.5 ± 
3.9 
31.1 ± 
7.7 
29.9 ± 
3.0 
29.5 ± 
4.2 
30.8 ± 
5.9 
29.0 ± 
3.8 
Na 
mmol/L 
144 ± 
1.1 
143 ± 
1.9 
142 ± 
1.5 
142 ± 
1.4 
144 ± 
1.0 
143 ± 
1.6 
Urea 
mmol/l 
7.13 ± 
0.7 
7.28 ± 
0.5 
6.49 ± 
0.9 
7.56 ± 
0.6 
6.59 ± 
0.8 
7.04 ± 
0.8 
Uric 
Acid 
48 ± 3 45 ±5 
(3) 
<DL(1) 
51 ± 6 62 ± 
12 
49 ± 5 54 ± 
12 
TBIL 
µmol/L 
5.38 ± 
0.28 
5.30 ± 
0.69 
5.73 ± 
0.83 
6.12 ± 
0.17** 
5.22 ± 
0.77 
5.01 ± 
0.71 
Zn 
µg/dL 
119 ± 
3 
136 ± 
6 
124 ± 
9 
125 ± 
3 
132 ± 
7 
114 ± 
10 
ROM 
IU/L 
297 ± 
16 
272 ± 
23 
274 ± 
26 
304 ± 
22 
279 ± 
11 
289 ± 
23 
SHP 
µmol/L 
349 ± 
6 
324 ± 
21 
331 ± 
25 
327 ± 
22 
328 ± 
17 
340 ± 
39 
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Stomach: An increased incidence and severity of submucosal glandular inflammation with 
eosinophilic granulocytes (a minimal degree is considered to be background) on day 6 was 
observed in –  
• 4/4 rats treated at 64 mg/kg (moderate),  
• 4/4 rats treated at 128 mg/kg (1 minimal, 3 slight),  
• 2/4 control rats (minimal).  
After a 3-week treatment-free period the submucosal glandular inflammation with eosinophilic 
granulocytes was observed to remain in –  
• 4/4 rats 2 slight, 2 moderate) treated at 64 mg/kg,   
• 4/4 rats (1 minimal, 3 slight) treated at 128 mg/kg,  
• 1/4 control rats (minimal). 
Liver: Inflammation (mixed inflammatory cells) occurred at day 6 in – 
• 3/4 rats treated at 64 mg/kg (2 slight, 1 moderate), 
• 1/4 rats at 128 mg/kg (moderate).  
Hepatocellular hypertrophy occurred at day 6 in – 
• 2/4 rats at 64 mg/kg (1 slight, 1 moderate),  
• 2/4 rats at 128 mg/kg (slight).  
Hepatocellular necrosis occurred at day 6 in – 
• 1/4 rats at 64 mg/kg (minimal),  
• 1/4 rats at 128 mg/kg (slight).  
Single cell necrosis occurred at day 6 in – 
• all rats treated at 64 (1 minimal, 2 slight, 1 moderate),  
67 
 
•  all rats treated at 128 mg/kg (1 minimal, 1 slight, 2 moderate).  
Increased mitosis in the liver occurred at day 6 in – 
• 1/4 rats treated with 64 (moderate),   
• 1/4 rats treated at 128 mg/kg (moderate).  
In the animals autopsied at day 7 similar lesions were observed  consisting of – 
• 2/4 rats with Kupffer cell hypertrophy/hyperplasia (moderate),  
• 1/4 rats with vacuolation (slight),  
• 3/4 rats with inflammation (1 slight, 2 moderate), 
• 3/4 rats with single-cell necrosis (1 slight, 1 moderate, 1 marked).  
The minimal single cell necrosis in a single rat treated at 64 mg/kg is considered to be 
background. 
 
At 128 mg/kg CuCO3: 
Liver: Kupffer cell hypertrophy/hyperplasia occurred at day 6 in –  
• 2/4 rats (1 slight, 1 moderate) 
Hepatocellular vacuolation occurred at day 6 in –  
• 3/4 rats (slight) treated at 128 mg/kg CuO3. I 
In the second group of animals autopsied at day 7  similar  findings were observed in rats 
treated at 128 mg/kg CuO3 consisting of – 
• 2/4 rats with Kupffer cell hypertrophy/hyperplasia (moderate),  
• 1/4 rats with vacuolation (slight). 
Intestines: Ulcerations/erosions in the colon occurred at day 6 in –  
• 2/4 rats (slight) with oedema in 1/4 rats (minimal)  
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Inflammation occurred at day 6 in the rectum of –  
• 1/4 rats (minimal) with edema (slight).  
In the second group of animals autopsied at day 7 intestinal findings consisted of 
ulcerations/erosions and/or edema in – 
• the cecum of 1/4 rats (minimal),  
• the colon of 1/4 rats (slight),  
• the rectum of 3/4 rats (1 minimal, 1 slight, 1 moderate).  
In addition, increased apoptosis was observed in  
• the duodenum of 3/4 rats (2 slight, 1 moderate),  
• the ileum of 1/4 rats (moderate).  
Spleen: Lymphoid atrophy was observed in  
• the spleen of 2/4 rats (1 minimal, 1 slight) at day 6  
• the spleen of 2/4 rats (minimal) at day 7.  
Thymus: Lymphoid atrophy was observed in the thymus of 2/4 rats (moderate) at day 7. 
Kidneys: Tubular necrosis occurred in 2/4 rats (marked) with hyaline casts in the same 2/4 rats 
(moderate) at day 6. Also at day 7 tubular degeneration/regeneration was observed in 2/4 rats 
(moderate) with tubular intranuclear inclusions (moderate). 
Testes: Moderate degeneration of germ cells (including slight multinucleated giant cells) and 
marked spermatid retention was observed in 1/4 rats at day 7.  
Seminal vesicles: Decreased fluid was observed in the seminal vesicles of 4/4 rats (slight) at 
day 6 which was also present at day 7 in 4/4 rats (1 minimal, 2 slight, 1 moderate). 
Bone marrow: Increased myeloid elements/increased erythroid elements in the bone marrow 
of 3/4 rats (2 minimal, 1 moderate) and myeloid hyperplasia was observed in 3/4 rats (slight) 
at day 7. 
Cu content of tissues - Cu content of tissues after 5 consecutive days of CuCO3 oral 
administration is presented in Table 17.  For the liver, kidney and thymus, at the lower dose 
investigates (64 mg/kg) an increase in Cu content was noted. For the highest dose (128 mg/kg) 
increases in Cu content were observed in liver, lung, kidney, spleen, thymus, and mesenteric 
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lymph node. At day 26 the increased levels of Cu in liver and kidney were returned to levels in 
the control animal range. 
 
Table A. 17 Cu (µg/g tissue) in organs of male rats after 5 days consecutive oral administration of CuCO3. 
 
 
Cytokine protein – Figure A.15 below shows the cytokines which were detected in each of the 
tissues examined following CuCO3 treatment.  In these exposures, doses of 8, 16 and 32mg/kg 
were not examined in stomach, colon and duodenum tissues.  At the highest doses of 64 and 
128mg/kg CuCO3, there was a significant (p<0.001) increase in IL-1α in the duodenum, liver 
and colon samples.  There was no significant increase in IL-1β in any of the tissues at the 
highest dose of CuCO3 and no evidence of IL-6 or IL-13 in any tissue samples (data not shown).  
There was a significant decrease in IL-12 production in liver tissue at the two highest doses of 
64 and 128mg/kg (p<0.001; p<0.01 respectively). 
CuCO3 Day 6     Day 
26 
 
Dose  0 
mg/kg 
 64 
mg/kg 
128 
mg/kg 
 0 
mg/kg 
64 
mg/kg 
        
Liver 13±0.5a  451±58*** 1399±307 
(8)*** 
 13±1 29±9* 
Lung 8±0.4  9±3 259±335 
(8)* 
 7±0.3 7±0.6 
Kidney  29±6  55±13 
(3)* 
810±369 
(8)*** 
 36±17 28±4 
Spleen 5±0.2  6±0.6 35±26 
(7)* 
 5±0.2 5±0.3 
Thymus 4±0.5  6±0.6*** 29±20 
(8)*** 
 3±0.3 3±0.4 
Mesenteric 
Lymph 
Node MLN 
6±1  7±1 48±23 
(8)** 
 6±3 6±2 
Testes  11±0.3  12±0.2* 15±3 
(8)** 
 11±0.2 13±1** 
Brain 
cortex 
9±0.2  10±0.4* 11±1 
(8)*** 
 9±0.5 10±7 
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Figure A. 15. Cytokine concentrations (µg/mg protein) present in selected tissues from rats dosed orally with 8 to 128mg/kg 
of CuCO3 and sacrificed 6 days post exposure.  Data represent the mean±SEM of each cytokine detected (µg/mg protein) and 
represents data from four separate animals.  (*p<0.05; **p<0.01; ***p<0.001 compared with the control). 
 
 
GSH and reduced GSH in the liver - There was no significant change in the concentration of 
both total and reduced GSH in the liver of animals treated orally with different doses of CuCO3. 
 
Conclusions on oral CuCO3 administration. 
 
Oral CuCO3 administration for 5 consecutive days clearly induced toxicity in male rats as 
indicated by the weight loss of the animals in the highest dose investigated (128 mg/kg). For 
this dose, it was not possible to maintain the animals for a recovery period of three weeks after 
the last administration. In addition, to the body weight loss, a reduction in organ weight was 
noted for the heart, liver, spleen, thymus and an increase for the adrenals. At one dose lower 
(64 mg/kg) such weight alterations were not present. An increase in WBC was observed that 
could be attributed to an absolute increase of neutrophilic granulocytes. While the relative 
percentage of lymphocytes was decreased, the absolute number of lymphocytes remained 
C o n tro l 8 1 6 3 2 6 4 1 2 8
0
2 0
4 0
6 0
8 0
IL -1 
S to m a c h
D u o d e n u m
C o lo n
C u C O 3  D o s e  (m g /k g )
IL
-1

 (
p
g
/m
g
 p
r
o
te
in
)
L iv e r
Ileum
* * *
* * *
C o n tro l 8 1 6 3 2 6 4 1 2 8
0
2 0 0
4 0 0
6 0 0
8 0 0
IL -1 
S to m a c h
D u o d e n u m
C o lo n
C u C O 3  D o s e  (m g /k g )
IL
-1

 (
p
g
/m
g
 p
r
o
te
in
)
L iv e r
Ileum
C o n tro l 8 1 6 3 2 6 4 1 2 8
0
1
2
3
4
IL -1 2
S to m a c h
D u o d e n u m
C o lo n
C u C O 3  D o s e  (m g /k g )
IL
-1
2
 (
p
g
/m
g
 p
r
o
te
in
)
L iv e r
Ileum
*
* * *
* *
C o n tro l 8 1 6 3 2 6 4 1 2 8
0
2 0
4 0
6 0
T N F -
S to m a c h
D u o d e n u m
C o lo n
T
N
F
- 
 (
p
g
/m
g
 p
r
o
te
in
)
C u C O 3  D o s e  (m g /k g )
L iv e r
Ileum
* *
*
O ra l S tu d y  C u C O 3
71 
 
similar to control levels. Also for red blood cell parameters (RBC, HgB and Hct) increase was 
observed. After a recovery period of 21 days these effects were no longer visible. The clinical 
chemistry data showed alterations in various liver enzymes including ALT, AST, ALP, while 
the increase in LDH may indicate cell damage. Most of these clinical chemistry parameters 
returned to normal values after the recovery period of 21 days.  
The histopathology confirmed the severe toxicity of the 5-day oral administration of CuCO3. 
There were severe pathological lesions in the GI-tract with inflammation in the stomach, and 
cell death (apoptosis) in duodenum and ileum, and ulcerative lesions/erosions in the large 
intestines (cecum, colon, rectum). The liver showed inflammation, hepatocellular hypertrophy, 
hepatocellular necrosis and single cell necrosis, especially in the two high dose groups (64 
mg/kg and 128 mg/kg). In the lymphoid organs spleen and thymus, severe lymphocyte 
depletion was present. In contrast in the bone marrow, an increase in myeloid white blood cell 
precursors was present, which may be present as a compensatory mechanism for the lymphoid 
depletion in spleen and thymus. In the kidney tubular necrosis, a tubular 
degeneration/regeneration was observed. 
In a number of affected organs, the Cu measured was increased compared to the values in 
control animals including liver, kidney, spleen, and thymus. Other organs showing an increase 
in Cu content are lung, mesenteric lymph node testes and brain. However, the increases in 
testes and brain are limited.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
